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ABSTRACT

The human cytomegalovirus (HCMV) viral chemokine gene, UL146,
shows a high degree of variability in clinical isolates. The UL146-produced viral
chemokine, vCXCL-1, has homology to CXC chemokines and is predicted to be
an immune modulator that may contribute to the pathogenesis of HCMV
infections. In the analysis of clinical isolates from congenitally infected infants,
we found 11 distinct vCXCL-1 clades. Although the four cysteine residues that
create two disulfide bonds providing the essential structure for CXC
chemokines,are conserved, the N-loop region, which is important for receptor
binding and activation, was hypervariable. One clade also contained a modified
glutamic acid-leucine-arginine (ELR) motif (asparagine-glycine-arginine / NGR),
which regulates binding to CXCR1 and CXCR2 receptors.

Based on this

sequence information, we hypothesize that these proteins differentially activate
neutrophils, which may have a role in HCMV pathogenesis. To address these
functional differences, we produced representative vCXCL-1 proteins from each
of the 11 clades using a baculovirus protein expression system.

Using

competition binding assays, we have examined their binding affinities to either
CXCR1 or CXCR2 expressed on HEK293 cells. All vCXCL-1s bound to CXCR2
with different binding affinities. Interestingly, only three vCXCL-1s bound to
CXCR1 while the others demonstrated did not.

We analyzed functional

differences between the vCXCL-1s in calcium mobilization, adhesion molecule
induction, and chemotaxis on human peripheral blood neutrophils (PBNs).
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Although the binding affinities to CXCR2 and/or CXCR1 were variable, all
vCXCL-1s were capable of inducing intracellular calcium mobilization in PBNs
and upregulating adhesion molecules on the surface of PBNs to similar levels as
human CXCL1. However, the potency of the vCXCL-1s in the chemotaxis of
neutrophils varied and was affinity independent. We also examined secondary
chemokine production upon vCXCL-1 treatment on neutrophil-like HL60 T2 cells
using real-time PCR.

The results showed CCL22 induction was affinity

dependent. Taken together, these results provide insights into the potential role
of vCXCL-1 in HCMV pathogenesis and how the variability in these chemokines
can affect neutrophil function.
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Chapter 1
INTRODUCTION
Human cytomegalovirus (HCMV) is a ubiquitous beta-herpesvirus
infecting 50-90% of the population with higher infection rates found in people with
lower

socioeconomic

status.

Generally,

HCMV

infection

is

generally

asymptomatic or causing mononucleosis in immunocompetent individuals, but
high levels of morbidity and mortality rates are observed in immunocompromised
individuals following organ transplantation or untreated HIV infection.

For

example, 80% of kidney recipients acquire a primary CMV infection following
transplantation [1] and an 84% mortality rate was observed in bone marrow
recipients [2, 3]. Also, HCMV disease occurred in 44% of AIDS patients before
the introduction of antiretroviral therapy [4].

In addition, HCMV is the most

common congenitally acquired infection in the United States. Each year, about
1% of all newborns in the United States are infected with HCMV congenitally [5],
reaching almost 40,000 newborns per year [6]. 0.1% of these infected infants
display

clinical

manifestations

at

birth,

such

as

microcephaly,

hepatosplenomegaly, jaundice, petechiae, or chorioretinitis [7] and up to 80% of
those develop long-term neurodevelopmental sequelae, such as lower
intelligence/developmental quotient (IQ/DQ), hearing loss, or mental retardation
[6, 8]. Newborns that are asymptomatic at birth also can develop permanent
damage, which may not manifest until they are older [9]. Due to this high rate of
disease development and lasting morbidity, the Institute of Medicine ranked the
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development of a CMV vaccine as a top priority based on the overall cost of
treatment and human suffering [10].
HCMV is a large dsDNA virus that comprises 165-252 kb [11, 12]. HCMV
encodes over 200 viral proteins [13, 14], yet they have evolved survival
mechanisms to overcome host immune responses that eventually contribute to
HCMV pathogenesis and disease development [15]. Yu et al showed 41 HCMV
ORFs in the laboratory-adapted strain, AD169, that are essential for viral
replication in vitro, such as DNA polymerase, capsid, matrix and envelope
proteins [16].

He also found 88 “nonessential” genes for efficient HCMV

replication in vitro. Some of these nonessential HCMV genes are homologous to
the host genes: class I MHC proteins [17-21], TCR gamma chain [22], IL-10 [23],
TNF receptor [24], and chemokines [25]. Among those nonessential genes, the
15 kb UL/b’ genomic region of the virulent Toledo strain contains at least 19 open
reading frames (ORFs) which are not present in laboratory-adapted strains such
as the AD169 strain [25, 26]. Two ORFs in this region show homology to host
chemokines: UL146 and UL147 that encode vCXCL-1 (also called pUL146) and
vCXCL-2 (also called pUL147) [25]. These chemokine homologs genes show
hypervariability among different viral strains [27].

Moreover, the vCXCL-1

chemokine from the Toledo strain, vCXCL-1Tol, induces neutrophil chemotaxis
and calcium mobilization [28]. Therefore, evaluations of the function of vCXCL1s will provide a better understanding of HCMV pathogenesis that may ultimately
facilitate development of an effective vaccine or novel antiviral agents against
CMV.
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Chapter 2
LITERATURE REVIEW

I. Chemokines and Chemokine Receptors
Chemokines
Chemokines are small chemotactic cytokines (approximately 8-12 kDa in
size) that mediate their signaling through G-protein coupled receptors [29, 30].
They are classified by the presence of conserved cysteines that define the
protein structure.

Chemokines are divided into C, CC, CXC, and CX3C

chemokines based on the number of conserved cysteine residues and the
spacing of two cysteines at the N-terminus. For example, CXC chemokine (α
subfamily) members have two cysteines separated by an amino acid residue
while the CC chemokine (β subfamily) has two juxtaposed cysteine residues.
The C chemokine family (γ subfamily) has only one cysteine at the N-terminus
and the CX3C chemokine (δ subfamily) contains two cysteines separated by
three amino acids [31]. CXC chemokines can be further subdivided into ELR or
non-ELR CXC chemokine dependent upon the presence of a glutamate-leucinearginine (ELR) motif directly preceding the CXC motif [32].
The ELR motif is critical to induce activation and migration of neutrophils
[32]. The ELR CXC chemokines bind to CXCR1 and/or CXCR2, and it has been
shown that CXCR2 activation is mainly responsible for neutrophil activation [33].
Single amino acid substitutions in the ELR motif showed all three residues,
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especially arginine, are sensitive to modification and are critically important for
CXCL8 (IL-8) function [34, 35]. A further demonstration of the importance of this
motif is that the addition of ELR to the N-terminal domain of a non-ELR CXC
chemokine, CXCL4 (PF4), transforms it into a neutrophil chemoattractant [34]
although another non-ELR CXC chemokine, CXCL10 (IP-10), requires additional
Gly31 and Pro32 changes in order to become a fully functional chemokine on
human neutrophils [36]. ELR CXC chemokines also have angiogenic properties.
CXCL8 (IL-8), CXCL7 (NAP-2), CXCL1 (GRO-α), CXCL2 (GRO-β), CXCL3
(GRO-γ) and CXCL5 (ENA-78) have been reported as proangiogenic agents
through the recruitment of endothelial cells [37, 38].

Although, angiostatic

activities of ELR CXC chemokines were also reported for CXCL1 (GRO-α),
CXCL2 (GRO-β), and CXCL3 (GRO-γ) [39], the concentration was 1000-fold
higher (1-10 uM) than what was used for its angiogenic activity (1-10 nM) [40,
41].

This implies that at high concentrations ELR CXC chemokines are

angiostatic while at low concentrations they are angiogenic.
In contrast to ELR CXC chemokines, many non-ELR CXC chemokines
have angiostatic properties and almost exclusively attract cells other than
neutrophils [32, 40].

For instance, CXCL10 (IP-10) was reported to attract

monocytes, T lymphocytes, and NK cells [42, 43]. CXCL9 (MIG) was shown to
attract tumor-infiltrating T lymphocytes [44].

CXCL12 (SDF-1) stimulates the

proliferation of B cell progenitors and was also termed PBSF (pre-B cell growth
stimulating factor) [45]. Subsequent studies showed that synthetic CXCL12 also
stimulates monocytes and peripheral blood lymphocytes through intracellular
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calcium mobilization and chemotaxis [46, 47]. This illustrates the specificity that
the ELR motif brings to chemokine function.
The CC chemokines are the largest family of chemokines and attract a
variety of cell types including monocytes, basophils, eosinophils, and dendritic
cells [48].

CCL2 (MCP-1) was the first CC chemokine to be biologically

characterized and shown to attract monocytes but not neutrophils [49].

The

monocyte chemotactic proteins (MCPs) are not only effective on monocytes [5052], but also attract CD4+ and CD8+ T lymphocytes [53-55] and basophils [5659]. CCL5 (RANTES) [60] and CCL11 (eotaxin) [61] were also shown to be
powerful attractants of eosinophils.
The C and CX3C chemokines are regarded as two minor families because
they contain few members and are highly specific for a few receptors. The CX3C
family has three amino acids separating the initial pair of cysteines and has only
one member, CX3CL1 (fractalkine) [62]. CX3CL1 is produced as a long protein
(373 amino acid) with an extended mucin-like stalk and a chemokine domain on
top [62]. CX3CL1 is bound to the surface of cells, such as endothelial cells and
promotes strong adhesion of leukocytes to endothelial cells. This membranebound CX3CL1 can also be cleaved and become a soluble chemokine (85 or 95
kDa) that attracts T cells and monocytes [62-64].
Lastly, the C chemokine family is represented by two chemokines, XCL1
(lymphotactin α) and XCL2 (lymphotactin β). They lack two of the four cysteine
residues that are characteristic of chemokines [65]. Lymphotactin is expressed
in progenitor T cells, activated CD8+ T cells, and natural killer (NK) cells [65, 66].
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It has been shown to be a potent chemoattractant for both CD4+ and CD8+ T
cells, natural killer (NK) cells, but not monocytes [65, 67-69]. Lymphotactin has
also been reported to be chemotactic for B cells and neutrophils through XCR1
receptor [70].

Chemokine Receptors
Chemokines mediate their signals through 7 transmembrane G-protein
coupled receptors (GPCR).

Since GPCRs are generally known to be

promiscuous for their ligands, it is reasonable that there are fewer receptors than
chemokines [71]. Complex and multiple downstream signaling events, however,
are possible due to the large number of heterotrimeric G proteins, such as α, β,
and γ subunits, and β-arrestin [72, 73]. To date, 17 Gα, 5 Gβ, and 12 Gγ proteins
have been found [73, 74].

Chemokine binding to a GPCR induces

conformational changes and triggers its function as a guanine-nucleotide
exchange factor (GEF) that exchanges GDP for GTP on the Gα subunit. This
exchange causes the dissociation of the Gα subunit from the Gβγ dimer, both of
which activate several down stream effectors [75, 76].

In addition to GTP

mediated signaling, G protein receptor kinases (GRKs) and β-arrestins also
control signaling [77]. GRKs phosphorylates serine and threonine residues in the
C-terminus allowing β-arrestin binding. β-arrestins then prevent association of
the G protein with the GPCR (desensitization) [78].

Additionally, the GRK-

arrestin system promotes clathrin-mediated internalization of the inactivated
GPCR to endosomal compartments for subsequent degradation or recycling to
6

the cell surface [79, 80]. Interestingly, β-arrestins have also been shown to act
as adaptor proteins mediating signaling events downstream of the GPCR,
independently of G proteins activating mitogen-activated protein kinases
(MAPKs), SRC, nuclear factor-κB (NF-κB) and phosphoinositide 3-kinase (PI3K)
[78, 81, 82]. Therefore, various ligand binding with multiple combinations of G
proteins and complex signaling pathways from G proteins and β-arrestins can
generate numerous cellular effects from a similar ligands (Fig. 1).
Once the Gα subunit and the Gβγ dimer are dissociated, the Gα subunit
remains in the activated GTP-bound state until hydrolysis of GTP to GDP leads
to reassociation of the heterotrimer and termination of the signal by the regulator
of G-protein signaling protein (RGS) [83].

The α subunits of G proteins are

divided into four subfamilies: Gαs, Gαi/o, Gαq/11, and Gα12/13. Each Gα protein
activates several downstream effectors.

Typically Gαs protein stimulates

adenylyl cyclase (AC) and increases levels of cyclic AMP (cAMP) that
subsequently activates mitogen-activated protein kinase (MAPK) signaling
modules and protein kinase A (PKA) [84].

However, Gαi/o inhibits AC and

reduces cAMP levels that subsequently activates G-protein-coupled inwardly
rectifying

potassium

(GIRK)

channels

[85].

Gαq/11

protein

activates

phospholipase Cβ (PLCβ), and Gα12/13 subunit activates Rho guanine-nucleotide
exchange factors (GEFs) [86]. 8 Gα proteins are ubiquitous or widely distributed,
but 9 Gα proteins are expressed in selective cell types, such as neuronal cells,
retinal cells, or haematopoietic cells, etc (supplementary information of [87]). In
summary, GPCRs can induce differential signalings via activation of various G
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Figure 1. Basic scheme for GPCR activation and feedback of signaling.
Agonist exposure stimulates activation of GPCR, which leads to the dissociation
of G proteins into activated subunit and dimers and triggers the activation of
various effectors, such as adenylate cyclase and phospholipase C. The agonistoccupied GPCR is phosphorylated by GRKs, leading to signal desensitization,
binding of β-arrestin to the activated, phosphorylated GPCR and subsequent
endocytosis of the receptor. β-arrestin also initiate downstream signaling events.
(adopted from Ma and Pei, 2007).
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proteins that would also depend on the presence of specific G proteins in the cell
as well as the right GPCR conformation to stimulate different G proteins.
Dissociated Gβγ subunits also regulate a number of signaling pathways.
Gβγ mediates the phosphorylation of PLCβ as Gαq does [88, 89].
PLCβ

cleaves

phosphotidylinositol

4,5-bisphosphate

(PIP2)

to

Activated
inositol

triphosphate (IP3) and diacylglycerol (DAG). IP3 elicits calcium mobilization from
the endoplasmic reticulum (ER) into the cytoplasm, while DAG activates protein
kinase C (PKC) [90]. Transient intracellular calcium mobilization is frequently
used as a marker of cellular activation [91], whereas PKC activation is required to
upregulate β2 integrins, such as CD11b/CD18, in neutrophils and eosinophils
[92, 93].

In addition, Gβγ also stimulates Akt through phosphatidylinositol 3-

kinase (PI3K) as Gαs does through PKA [74]. It has been demonstrated that Akt
activation as well as ERK are responsible for chemotaxis of HL60 cells or
CXCR2 transfected HEK293 cells [94, 95]. As there are various Gα proteins,
there are 5 Gβ and 12 Gγ proteins that can compose numerous combinations
[73, 87].

Gβ and Gγ proteins are widely distributed except 1 Gβ and 5 Gγ

proteins are expressed in selective tissues, such as brain or taste buds
(supplementary information of [87]). Therefore, overlapping signaling cascades
through Gβγ can also increase the complexity of the signaling pathway.

CXC chemokine and chemokine receptor interaction
GPCR activation requires interaction with specific domains on the
chemokines. The N-terminus of both CC and CXC chemokines preceding the
9

first cysteine is considered an important region for receptor binding and activation
[30, 96-100]. For instance, N-terminal truncation mutants of the CXC chemokine
CXCL12 (SDF-1) revealed the eight residues proceeding first cysteine are
essential for receptor binding and the deletion of the first two residues generates
a receptor antagonist [101].

For CC chemokines, the entire 10 residues

preceding the first cysteine in CCL2 (MCP-1) are strictly required for full activity
[97, 98]. Manipulation of the N-terminus of CCL7 (MCP-3) and CCL5 (RANTES)
produced potent antagonists [99, 100]. This included a single methionine, which
converts CCL5 (RANTES) from an agonist to an antagonist. Furthermore, in
ELR CXC chemokines, mutations and domain swaps of CXCL1 (Groα) and
CXCL8 (IL-8) revealed that the Glu-Leu-Arg (ELR) motif is a critical motif for
receptor recognition and activation [102, 103]. Following the second cysteine is
a flexible N-loop of approximately ten residues, which is followed by a single turn
helix. The N-loop region has been shown to be responsible for receptor binding
and specificity [30, 35, 96, 104]. For example, Skelton et al. showed that CXCL8
(IL-8) and CXCR1 N-terminus fragment, CXCR1-p1, are found to interact along
the ELR and N-loop motifs of CXCL8 (IL-8) [105]. Furthermore, N-loop swaps
between CXCL8 (IL-8) and CXCL1 (Gro-α) and mutations in this region
demonstrated that the CXCL8 (IL-8) N-loop residues are critical for receptor
specificity [106], indicating the ELR motif is necessary for receptor recognition
and the N-loop region controls receptor specificity. Nevertheless, other regions
within the chemokine also contribute to receptor interactions as synthetic
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peptides comprising the N-terminus and the N-loop have reduced activities
compared to their full-length counterparts [32].
Chemokines bind to glycosaminoglycans (GAGs) due to their cationic
nature [107, 108]. CXCL8 (IL-8) binds to GAG through its C-terminal α-helix and
shows enhanced chemotactic activity on neutrophils when complexed to heparan
sulfate [109]. The GAG interaction on the cell surface or within the extracellular
matrix is thought to facilitate the retention of chemokines and subsequently
present it to the receptor expressed on the leukocyte cell surface, promoting cell
adhesion and activation [110]. This will also create a solid support for chemokine
gradients allowing the directed movement of cells under conditions of blood flow
at the endothelial surface. Several studies have shown the importance of GAG
binding on chemokine function. Gilat et al, using extracellular matrix (ECM)coated culture dishes, showed that CCL4 (MIP-1β) and CCL5 (RANTES)
leukocyte adhesion and chemotaxis is GAG-dependent [111].

In addition,

Proudfoot et al have shown that mutations in GAG binding sites of CCL2 (MCP1), CCL4 (MIP-1β), and CCL5 (RANTES) results in recruitment defects when
injected into the peritoneum of mice while they retain chemotactic activity in vitro;
thus, highlighting the importance of the chemokine-GAG interaction in vivo [112].
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II. Viral immune evasion and pathogenesis
Viral immune evasion
Viruses replicate in a host cell pirating cellular resources.

In order to

survive against host immune responses that recognize and eliminate virusinfected cells, viruses have evolved strategies to overcome or manipulate the
host immune system.

For instance, large DNA viruses such as β- and γ-

herpesviruses and some poxviruses have evolutionally acquired and modified
host chemokines or chemokine receptors [113-115].

These virally encoded

proteins are able to manipulate host immune responses, potentially leading to
better viral dissemination and establishment of latency [114, 116, 117].

For

dissemination purpose, viruses may attract immune cells through viral
chemokines for infection and viral chemokine receptors to facilitate cell migration
to sites of latency [114]. For immune system manipulation purposes, viruses
may attract specific cell types, such as Th2 leukocytes, so that cytotoxic T cell
(CTL) responses can be diminished [118, 119].

Viral pathogenesis
Herpesviruses are large double-stranded (ds) DNA viruses with 84–252
open reading frames (ORFs) [115, 120, 121]. Herpesviruses replicate in the
nucleus of the cell and undergo lytic replication and can establish latency.
Following a primary productive infection, the virus is not completely eliminated
from the host, but instead establishes a lifelong latent infection expressing only
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minimum viral proteins in the absence of detectable infectious virus [122, 123]. It
can reactivate at a later stage to generate new infectious virus and spread to a
new host. Herpesviruses are classified into three subfamilies, the α-, β-, and γherpesvirinae based on their genetic organization, homology, and tropism [124].
At least eight virus types are known to infect humans.

The α-herpesviruses

include herpes simplex virus 1 and 2 (HSV-1 and HSV-2; HHV-1 and HHV-2) and
varicella zoster virus (VZV, HHV-3). These viruses remain latent in neurons. The
β-herpesvirus subfamily includes cytomegalovirus (CMV, HHV-5), human
herpesvirus 6 (HHV-6), and human herpesvirus 7 (HHV-7) and infects many cell
types compared to α-herpesviruses. Human CMV DNA has been found in a wide
variety of organs [125]. Cells containing latent HCMV DNA has been found in
monocyte/macrophage lineages [126-129] and hematopoietic progenitor cells
[130-135]. In Murine CMV, latent DNA has been detected in endothelial cells of
diverse organs including heart, kidney, liver, lung, spleen, brain, salivary glands,
and bone marrow, and macrophages in the lungs [136, 137].

The γ-

herpesviruses include Epstein–Barr virus (EBV, HHV-4) and Kaposi’s sarcomaassociated herpesvirus (KSHV, HHV-8).

They infect lymphocytes and

endothelial cells and can induce cellular transformation [138].
Poxviruses are also large dsDNA viruses with a 130–360 kbp genome that
encodes over 230 proteins (See www.poxvirus.org for more detail). In contrast to
herpesviruses, poxvirus replication and the formation of progeny viruses take
place in the cytoplasm, which is independent of the host nuclear machinery [117,
139].

Poxviruses generally infect a variety animal hosts and causes acute
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infections with abrupt onset of fever and skin lesions without establishing latency.
Some families of poxvirus, however, can cause life-threatening infections.
Variola virus, the causative agent of smallpox, was one of the most virulent
human pathogens, with a mortality rate as high as 40%. Vaccinia virus has been
used as a vaccine and led to the 1979 eradication of smallpox worldwide [140].
Molluscum contagiosum virus (MCV) is the only poxvirus member that infects
humans exclusively.

MCV commonly spreads through skin-to-skin contact

causing skin lesions that are dome-shaped and pearly in appearance. Infection
is usually benign and painless.

The Orf virus causes disease with papulo-

vesicular lesions on the hand or face through direct contact with infected sheep
and goats. Often times when poxviruses cross species, disease is generally
much more mild compared to the original host. There are many more members
of the poxvirus family, but are beyond the scope of this review. Importantly, this
large DNA virus family that causes acute infection produces an array immune
modulating proteins similar to herpesviruses.

III. Viral chemokine homologs
CXC chemokine homologs in CMV
Human CMV (HCMV) have two ORFs, UL146 and UL147, encoding CXC
chemokine homologs, vCXCL-1 and vCXCL-2, respectively [25] (Table 1).
Recently a presentation at the International Herpesvirus Workshop (Salt Lake
City, 2010) indicated that vCXCL-2 is not secreted and is able to downregulate
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Table 1. Cytomegalovirus chemokine-like genes (adapted from Beisser et
al. 2008).
CMV
species

HCMV

Gene
(product
name)

GenBank
accession

References

UL128

NC_006273

[141, 142]

NC_006273

[143]

NC_006273

[143]

UL128

AF480884

[141, 142]

UL146
(vCXCL–1)

AF480884

[144]

UL146A

AF480884

[11]

UL147

AF480884

[11]

UL156

AF480884

[11]

Splice variant may encode CXC
chemokine, not present in other CMVs

UL157

AF480884

[11]

UL146-like, not present in other CMVs

rhUL128

DQ120516

[145]

Intact in RhCMV 180.92, not present in
RhCMV68.1

rh158

AY186194

[145]

Intact in 68.1, not present in 180.92

rh156.2

DQ120516

[145]

AF232689

[146]

AF232689

[146]

U68299

[147]

UL146
(vCXCL–1)
UL147
(vCXCL–2)

Comments
Intact in AD169, disrupted in Merlin and
Toledo
Intact in Towne, Toledo, Merlin, lost in
AD169
Intact in Towne, Toledo, Merlin, lost in
AD169
Disrupted

UL146-like, not present in other CMVs

CCMV

RhCMV

RCMV

MCMV

r129 (RCK–
3/ ECK–3)
r131 (RCK–
2)
m131–129
(MCK–1;
MCK–2)

GPCMV

GPCMV-MIP

AF500307

[148, 149]

HHV–6

U83A

NC_001664

[150, 151]
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Unique, MIP–1-like

NK activation with cooperation of UL142 [152]. Chimpanzee CMV (CCMV) also
encodes homologs of UL146 and UL147 as well as the UL146-related gene
UL146a and UL157 that are not present in other CMVs [11].
(RhCMV) encodes one homolog of UL147, rh158 [153].

Rhesus CMV

It will be interesting to

determine whether these homologues in other species have the same NK
inhibitory functions as UL147 from HCMV.
Yu et al showed that only 41 genes out of 150 ORFs in the lab-adapted
AD169 strain are essential for efficient viral replication in vitro, which indicates
many viral genes may be utilized for viral survival in vivo [16].

The virulent

Toledo strain contains at least 19 open reading frames (ORF) in the 15 kb, UL/b’
region, which are not present in AD169 and are not essential for virus replication
in vitro [25, 26]. This has lead to speculation that these genes may have a role in
HCMV pathogenesis. UL146 and UL147 chemokine genes reside in this UL/b’
[25]. UL146 ORF from the Toledo strain has been shown to produce a functional
CXC chemokine called vCXCL-1Tol [143]. vCXCL-1Tol induced chemotaxis and
intracellular calcium mobilization in human neutrophils at comparable levels to
host chemokines. Initially, vCXCL-1Tol was reported to bind exclusively to the
human CXCR2 (hCXCR2) chemokine receptor [143]. However, Lüttichau et al
recently showed that vCXCL-1Tol can bind not only hCXCR2 but also hCXCR1
[154], similar to that of the host chemokine, CXCL8 (IL-8). A deletion mutant of
UL146-UL147 showed that it impairs viral passage to neutrophils while its
tropism for other cell types is retained [142]. This result provides a potential role
for vCXCL-1 in HCMV dissemination.
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Interestingly, sequencing of the entire CMV genome has shown that the
UL146 gene is one of the most variable genes in the entire HCMV genome [26,
27, 155-160]. For instance, Dolan et al demonstrated HCMV genetic variability
using a nucleotide divergence assay [27]. He showed high levels of variability in
the RL11 gene families at left ends of UL and in the UL139, UL144, and UL146 at
right ends of UL. The proteins encoded by the RL11 gene family have potential
roles in tropism [161]; a UL9 mutant from Towne grows better in HFFs than wild
type virus while a UL10 mutant grows better in epithelial cells than wild type
virus, although Yu et al did not find enhanced growth of UL9 mutants from AD169
in HFFs [16], which is possibly due to the use of different parental viruses. The
UL139 protein shares sequence homology with human CD24 [162], a cellsurface sialoglycoprotein. It is expressed on immature cells modulating B-cell
activation and on many cancers, such as non-small cell lung cancer, breast
cancer, and prostatic cancer and correlates with tumor metastasis [163]. Qi et al,
however, did not find an association between UL139 genotypes and the clinical
outcomes [162]. The UL144 protein has limited homology to the herpes simplex
virus entry mediator (HVEM), a member of the tumor necrosis factor receptor
(TNFR) superfamily [164].

Research on an association between UL144

genotypes and clinical outcomes showed no strong association [165-169] while
Arav-Boger et al reported otherwise [156, 170].

Research regarding

polymorphisms of UL146 from clinical isolates showed 4% identity (5 residues)
and 5% similarity (6 residues) to each other [160]. It was postulated that this
variability might correlate with the severity of CMV disease however no clear
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relationship in this regard has been identified [158, 159, 165] and the function of
the UL146 polymorphisms remains to be determined.

CC chemokine homologs in CMV
HCMV has one ORF with limited homology to CC chemokine, UL128 [141], and
UL130 that encode a protein containing a putative C chemokine fold [171].
CCMV and RhCMV 180.92 also have a UL128 ORF with homology to CC
chemokines [141, 142, 145].

Murine CMV (MCMV) contains spliced genes,

m131 and m129, which produce the CC chemokine homolog, MCK-2 [147, 172].
Rat CMV (RCMV) also has both r131 and r129, but r131 has limited homology to
either m131 and m129 [173].

Guinea pig CMV (GPCMV), also known as

CavHV2_GP1, contains an ORF with limited homology to the CC chemokine
MIP-1 [148, 174].
The HCMV UL128 protein, however, is a non-functional chemokine due to
a partial inversion or frame shift mutation in clinical HCMV strains such as Toledo
and Merlin [141]. Although the UL130 protein contains a putative C chemokine
fold [171], functional data of UL130 as chemokine is lacking. Interestingly, the
UL128 locus (UL128L) that comprises UL128, UL130 and UL131A was found to
be essential for growth in endothelial cells, dendritic cells and epithelial cells, and
transmission to leukocytes [142, 175, 176]. The UL128L proteins form a complex
with glycoprotein H and L (gH/gL) on the virion surface [177]. The gH/gL/UL128L
complex mediates entry of CMV into endothelial and epithelial cells whereas the
gH/gL/gO complexes mediate virus entry into fibroblasts [176, 177]. So even
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though these have homology to chemokines, they more than likely have a role in
entry.
MCMV m131 and m129 genes generate a spliced mRNA that encodes the
CC chemokine homolog, MCK-2 [147].

A product of m131, MCK-1, was

originally described as a functional chemokine that induces calcium mobilization
in peritoneal exudate cells in vitro from MCMV-infected mice [178]. MCK-1 was
soon re-characterized as a part of a CC chemokine including a long carboxyterminal domain, which includes the entire m129 ORF [147, 172]. In vivo studies
with MCMV mutants that delete m131/129 or a mutated m131 gene show a
defect in dissemination to the salivary gland [179, 180] demonstrating that MCK2 is important for viral dissemination in vivo. The mutant MCMV with a defective
MCK-2 protein developed less inflammation at the site of inoculation and reduced
dissemination to the salivary glands [179, 180].

MCK-2 can recruit myeloid

progenitor cells [181] and monocytes [178], which not only contribute to MCMV
dissemination to the salivary gland but could also provide a reservoir for
establishing latency [130, 137, 182, 183].
As noted, RCMV contains the r131 gene that shows homology to both
MCMV m131 and m129 [173]. The RCMV r131 ORF encodes a functional CC
chemokine, pr131, which is essential for viral reproduction in the salivary glands
[146].

When RCMV deletion mutants lacking r131 were inoculated into

immunocompromised rats, RCMV was not able to establish a high-titer infection
in the salivary gland. In a rat footpad infection, this mutant showed significantly
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reduced swelling than did wild type RCMV, which mimics what was shown for
MCK-2 in MCMV.
GPCMV encodes a unique, MIP-1 CC chemokine homolog, GPCMV-MIP,
which is not conserved in other animal CMVs [148]. This gene encodes an 11
kDa protein, which then yields an 8.6 kDa mature polypeptide. Phylogenetic
analysis indicated GPCMV-MIP has homology to the macrophage inflammatory
protein 1 (MIP-1α / CCL3) and hemofiltrate CC-chemokine 1 (HCC-1 / CCL14).
MIP-1α and HCC-1 are known to enhance the proliferation of CD34+ myeloid
progenitor cells, which could be used to harbor latent GPCMV or to disseminate
the virus in vivo [184]. Functional assays showed that GPCMV-MIP mobilizes
equivalent levels of intracellular calcium mobilization and chemotaxis in hCCR1
transfectants [149] as CCL3 (MIP-1α) stimulation [185]. However, GPCMV-MIP
was not active on hCCR2 or hCCR5, which are the targets of CCL3 (MIP-1α).
The intracochlear inoculation of a recombinant GPCMV lacking the GPCMV-MIP
homolog resulted in less hearing loss compared to wild type GPCMV infection
[186] indicating GPCMV-MIP has roles in CMV pathogenesis.

CC chemokine homologs in other herpesviruses
The U83 protein of human herpesvirus 6 (HHV-6) has a unique CXXCC
sequence, which may be interpreted as a CC or/and CX3C chemokine [187].
However, the protein product of U83 gene was designated vCCL4 because it
causes intracellular calcium mobilization and chemotaxis exclusively through the
CCR2 receptor [188]. The HHV-6A (variant A) U83 gene encodes a 97 amino
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acid protein whereas HHV-6B (variant B) encodes one of 113 amino acids [189].
As noted, vCCL4 of HHV-6B, also known as U83B while that of HHV-6A is U83A,
is a selective but weak CCR2 agonist, inducing calcium mobilization and
chemotaxis of THP-1 cells and CCR2 transfected L1.2 cells [187, 188]. CCR2 is
expressed on monocytes, activated T cells, B cells, and immature dendritic cells
[190, 191]. HHV-6 predominantly infects and replicates in CD4 T cells [192] and
establishes latency in monocytes [193]. Furthermore, it has been shown that
HHV-6 replication in immature monocyte-derived dendritic cells (MDDCs) is a
prerequisite for viral transmission to CD4+ T cells [194]. Therefore, it seems
sensible that vCCL4 attracts and HHV-6 utilizes those cells for viral
dissemination or the establishment of latency.

Although HHV-6A also has

cellular trophism for CD4+ T cell, its vCCL4 homolog (U83A) showed a broad
specificity for the chemokine receptors CCR1, CCR4, CCR5, CCR6, and CCR8
[151]. Because HHV-6A has been detected in skin biopsies and implicated in
cases of multiple sclerosis (MS), the broad specificity of vCCL4 (U83A) suggests
that its multiple cellular tropisms could contribute to pathogenesis of HHV6A.
Interestingly, vCCL4 (U83A) can also manipulate the functions of host
chemokines by delaying CCR5 internalization and blocking chemokine
stimulation so this chemokine could be multi functional [151, 195].
Kaposi’s sarcoma-associated herpesvirus (KSHV, HHV-8) is responsible
for the development of Kaposi’s sarcoma (KS, a cancer that causes patches of
abnormal tissue to grow under the skin), primary effusion lymphoma (PEL, a rare
aggressive type of B cell lymphoma), and multicentric Castleman’s disease
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(MCD, a rare benign follicular hyperplasia in germinal centers of B-cell follicles)
[196, 197]. KSHV encodes three CC chemokine homologs, vCCL1, 2, and 3
(vMIP1, 2, and 3) [198-200]. KSHV chemokines antagonize or stimulate host
chemokine receptors, induce angiogenesis, and reduce apoptosis as part of its
immune manipulation. vCCL1 (vMIP-1) is an agonist of CCR8 [198, 201, 202],
which is preferentially expressed on TH2 cells [203]. By attracting Th2 cells the
virus could limit activation of the Th1/CTL response allowing for increased
survival. Both vCCL1 and vCCL2 are also potent chemoattractants for
endothelial cells [204, 205], which appear to be required for angiogenesis and
potentially contribute to tumor development [206].

Furthermore, vCCL1 and

vCCL2 have anti-apoptotic effects in vitro. These viral chemokines enhanced the
survival rate of endothelial cells and therefore promoted viral replication [207].
vCCL2 (vMIP-2) is a broad spectrum chemokine antagonist covering all four
classes of chemokines (XCR, CCR, CXCR, and CX3CR), which are particularly
found on Th1 cells [202, 208-210]. The efficient antagonistic activity of vCCL2 in
vivo has been demonstrated in mouse and rat inflammatory models [209, 211,
212].

However, others have shown that vCCL2 can bind and activate cells

through CCR8, CCR3, and CCR5 present on Th2 cells, eosinophils, or cell lines
[204, 213-215]. In fact, KSHV lesions expressing vCCL2 have a predominance
of Th2 polarized cells compared to Th1 type cells based on cytokine profiles
within the lesion [214]. vCCL3 (vMIP-3) was originally found to act with low
potencies in CCR4 and CCR5 chemotaxis assays [200]. However, Lüttichau et
al. were unable to demonstrate any calcium mobilization in L1.2 cells stably
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transfected with those receptors but showed that vCCL3 selectively activates the
XCR1 receptor with higher potency than the endogenous ligand XCL1
(lymphotactin) [216].

CC chemokine homologs in poxviruses
In addition to herpesviruses, poxviruses also produce viral chemokines.
Molloscum contagiosum virus (MCV) is a poxvirus that causes benign tumors of
the skin or occasionally on mucous membranes.
higher

incidence

in

children

and

immunocompromised individuals [217].

is

an

It causes infections with a
opportunistic

infection

in

MCV encodes a CC chemokine

homolog, MC148 [218]. Sequence analysis originally predicted MC148 to be an
antagonist because the N-terminus of the protein, a region important for receptor
activation, is shorter compared to cellular CC chemokines [219]. In vitro analysis
demonstrated that MC148 inhibits the migration of monocytes, lymphocytes, and
neutrophils in response to a range of chemokines and is not an agonist for any of
the CC or CXC receptors tested [219, 220]. However, Lüttichau et al. compared
the antagonism of MC148 with its analog, a broad-spectrum chemokine
antagonist vCCL2 from HHV-8, and demonstrated that CCR8 is the sole receptor
for MC148 [208, 221]. Interestingly, vCCL2 attracts CCR8 expressing cells for
viral dissemination and survival [213] while MC148 acts as an antagonist. In fact,
molloscum contagiosum lesions lack inflammatory infiltrates and MC148 might
contribute to this feature of these lesions [222].
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Summary and Statement of Research Aims
The development of a HCMV vaccine or other effective therapeutic
treatment is upmost importance due to the high morbidity and mortality in HCMV
infected newborns and immunocompromised individuals. However, no vaccine
against CMV is currently available despite over three decades of effort. This is
mainly due to the limited understanding of HCMV pathogenesis including viral
dissemination. HCMV dissemination occurs via cell-associated viremia in cells of
hematopoietic origin including monocytes and neutrophils. Large dsDNA viruses
such as herpesviruses possess modified host chemokines that could alter the
response of leukocytes during viral infection [84-86].

For example, MCMV,

RCMV, and GPCMV encode CC chemokines such as MCK2, pr131, and
GPCMV-MIP, respectively.

MCK2 and pr131 induce inflammatory responses

that enhance virus dissemination to the salivary gland in vivo, while GPCMV-MIP
showed the induction of inflammatory responses in the inner ear that leads to
hearing loss. The UL146 ORF from the Toledo strain encodes a functional CXC
chemokine called vCXCL-1Tol [143]. Moreover, vCXCL-1s from different HCMV
strains showed hypervariability, which could be a determinant of HCMV
pathogenesis. Therefore, the analysis of the relationship between the vCXCL-1s
polymorphism and the clinical manifestations may provide a key to developing a
novel HCMV vaccine. In addition, evaluating the function of those vCXCL-1s will
broaden our understanding of HCMV pathogenesis in relation to immune evasion
strategies.
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The hypothesis of this dissertation is that polymorphisms of the viral
chemokine, vCXCL-1, elicit different functions or different levels of cellular
activation, which could contribute to HCMV pathogenesis.

To test this

hypothesis, the following research objectives were performed:

1. Analysis

of

the

relationship

between

polymorphisms

within

human

cytomegalovirus chemokine, vCXCL-1, and clinical manifestations in
congenitally infected children.

2. Expression of recombinant vCXCL-1s from different clinical isolates and
evaluation of their functions as a chemokine in vitro.
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Chapter 3
POLYMORPHISMS WITHIN HUMAN CYTOMEGALOVIRUS
CHEMOKINE (UL146/UL147) AND CYTOKINE RECEPTOR GENES
(UL144) ARE NOT PREDICTIVE OF SEQUELAE IN
CONGENITALLY INFECTED CHILDREN

This chapter is a publication by the same title published in the journal
Virology in 2008 by Jinho Heo, Susie Petheram, Gail Demmler, Jody R. Murph,
Stuart P. Adler, James Bale, and Tim E. Sparer.
Heo, J., Petheram, S., Demmler, G., Murph, J. R., Adler, S. P., Bale, J.,
and Sparer T. E., Polymorphisms within human cytomegalovirus chemokine
(UL146/UL147) and cytokine receptor genes (UL144) are not predictive of
sequelae in congenitally infected children. Virology. 378(1):86-96.
My use of we in this chapter refers to my coauthors and myself. My
primary contributions to this paper include (1) the majority of the lab work and (2)
most of the data analysis, and (3) most of the writing of this paper.

Abstract
Human cytomegalovirus (HCMV) viral chemokine, UL146, and TNF α- like
receptor UL144 genes show a high degree of hypervariability in clinical isolates.
These proteins are predicted to be immune modulators and may contribute to the
pathogenesis of HCMV infections. We analyzed the UL146 and UL144 genetic
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variation of 51 HCMV isolates from congenitally infected children and 13 isolates
from children in childcare.

There was no statistically significant correlation

between UL146 and UL144 genotypes and HCMV disease and/or sequelae.
However, there were some groups that had a relatively large proportion of
asymptomatic outcomes. These included UL146 group 8 (7/8 asymptomatic) and
UL146 group 10 (3/3 asymptomatic).

UL144 group B had 11/15 (73%)

asymptomatic. UL146 and UL144 genes remained stable in serial isolates from
children in daycare for intervals up to three years. These results indicate that
most UL146 and UL144 genotypes do not predict clinical sequelae following
congenital HCMV infections.

Introduction
Human

cytomegalovirus

(HCMV)

is

a

ubiquitous

β-herpesvirus,

congenitally infecting about 1% of all newborns in the United States [5]. 0.1% of
these infected infants display clinical manifestations at birth such as
microcephaly, hepatosplenomegaly, jaundice, petechiae, or chorioretinitis [7]. Of
those

with

clinical

symptoms

neurodevelopmental sequelae.

at

birth,

most

develop

long-term

100% of these children will have lower

intelligence/developmental quotient (IQ/DQ), 65% will have some hearing loss,
and 53% will be diagnosed with mental retardation [6, 8]. Even those newborns
that are asymptomatic at birth can develop clinical outcomes of hearing loss and
learning disabilities, which may not manifest themselves until they are older [9].
Due to this lasting morbidity, the Institute of Medicine recently ranked the
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development of a CMV vaccine as a top priority based on the overall cost and
human suffering [10]. To develop an adequate and effective vaccine or drug, a
thorough understanding of the viral proteins that cause clinical disease are
necessary.
The outcomes of congenital HCMV infections are determined by a variety
of factors. Timing of infection, cell types infected at the placental interface [223,
224], and maternal antibody titers [225] are among the factors that may affect
clinical outcomes. Several investigators have speculated that HCMV genes are
important in the pathogenesis of human infections. HCMV possesses genes that
are predicted to be involved in immune evasion that could function to increase
viral survival or spread [141, 171, 226-232]. There are a large number of open
reading frames (~62) in HCMV that are “non essential” for virus replication in vitro
but may have a role in immune evasion in vivo. The 15 kb, UL/b’ genomic region
of the virulent Toledo strain contains at least 19 open reading frames (ORFs)
which are not present in laboratory-adapted strains such as the AD169 strain [25,
26]. The products of two of these ORFs: vCXCL-1 (also called pUL146 and
vCXC-1) from the UL146 gene and vCXCL-2 (also called pUL147 and vCXC-2)
from the UL147 gene have limited homology to CXC chemokines [25]. UL147
has only limited variability in the coding region of the mature protein. Variability
is limited to the signal sequence portion of UL147. The vCXCL-1 chemokine
from the Toledo strain, vCXCL-1Tol, induces neutrophil chemotaxis and calcium
mobilization [28].

Recently, numerous HCMV genomes from clinical isolates

have been sequenced [26, 155, 157-159, 233, 234] and have shown that the
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UL146 gene, along with the UL139 [162] and UL144 genes, are some of the
most variable genes in the entire HCMV genome. The evolutionary reasons for
this variability are unknown.
One hint of the role that vCXCL-1 plays during in vivo infection comes
from early vaccine trials [235]. During this study, two strains, Toledo and Towne,
were inoculated into naïve adult volunteers and the degree of febrile illness
measured. The outcome of this study showed that the Toledo strain generated
febrile illness at a tenfold lower dose than Towne, implying that Toledo is more
virulent than Towne. When these genomes were sequenced, the UL146 genes
were shown to be significantly different. This example is commonly used as
proof of the role that vCXCL-1 plays in HCMV pathogenesis.
Because of the variability in UL146, it has been suggested that vCXCL-1
proteins correlate with differences in long-term outcomes following congenital
infections or during reactivation in immune compromised patients.

Several

groups have analyzed the association between disease outcomes and UL146
variability [155, 157-159, 233].

These clinical specimens were isolated from

immunocompromised adults or congenitally infected newborns within first three
weeks of life. In adult renal transplant patients there was no correlation with
clinical outcomes and UL146 genotypes [159]. In the congenital studies, the
analysis did not take into consideration long-term sequelae. The analysis of
congenitally infected infants was based solely on symptoms at birth [155, 157159, 233]. This could lead to an underestimate of the number of asymptomatic
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children as HCMV infections leading to learning disabilities or mental retardation
may not become apparent until months or years after birth [9].
Another member of UL/b’ region, UL144, is also variable and a potential
virulence factor [164]. This protein has limited similarity to the herpes simplex
virus entry mediator (HVEM), a member of the tumor necrosis factor receptor
superfamily (TNFRSF) [164]. The UL144 protein, however, does not bind any
known TNF-related ligands [24, 164, 166].

To date, only one ligand, the Ig

superfamily member B and T lymphocyte attenuator (BTLA), has been shown to
bind to the UL144 protein [236]. By binding to BTLA, UL144 could decrease
lymphocyte responses to HCMV. Recently, UL144 has been shown to activate
TNFR-activated factor 6 (TRAF6) leading to NFKB activation, a pleiotropic
transcription factor [24]. NFKB activation enhances expression of the chemokine
CCL22, which attracts Th2 and regulatory T cells diminishing Th1 response.
Therefore, the authors speculate that upregulation of CCL22 may help HCMV
evade immune surveillance, resulting in increased viral spread. Data regarding
the association between UL144 genotypes and the outcomes of congenital
infection is conflicting. While Arav-Boger et al reported an association [156, 170],
others have not [165-169].
Our study addresses whether an association exists between specific
UL146, UL147, and UL144 genotypes and symptoms at birth in congenitally
infected children. Many of these children that were asymptomatic at birth were
followed for several years to ensure there were no long-term sequelae.

In

addition, serial isolates from children who shed HCMV over long periods of time
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were analyzed to examine whether UL146 hypervariability is driven via immune
pressure.

Materials and Methods
Clinical subjects and specimens
HCMV isolates from symptomatic and asymptomatic congenitally infected
children were obtained for phylogenetic analysis from two geographically distant
locations at four facilities: 40 HCMV isolates from Iowa (four hospitals in Iowa
City and Cedar Rapids, IA) and 11 isolates from Texas. Six isolates from the
Texas clinic were from a previous study [165].

Together, there are 18

symptomatic (K.P., Sk, A.B., P.L., Ca, 100546, 101027, 102124, 102226, 102410,
300584, TX03, TX11, TX12, TX20, TX21, TX24, and TX30) and 33
asymptomatic children (100427, 100457, 100691, 100738, 100751, 101142,
101329, 101430, 101465, 102429, 200164, 200550, 201334, 201370, 300016,
300482, 300521, 300667, 301217, 301699, 302281, 400191, 400328, 400340,
400600, 400818, 400865, 401058, 401361, TX05, TX15, TX25, and TX32)
(Table 2).
For the evolution of UL146 over time, 13 serial viral isolates from six
children attending six day care centers in Virginia were grown in vitro and
sequenced (Table 3).

31

DNA Isolation
DNA was isolated from the Iowa and Texas clinical isolates as previously
described [165]. HCMV infected MRC-5 cells from the Virginia Commonwealth
University (VCU) study were maintained until 70 to 80% cytopathic effect (CPE)
was attained.

Cold Tris/EDTA buffer (0.5 ml) with 10% SDS (50 ul) and

proteinase K (100 ug/ml) was added to the cell pellets and incubated for one
hour at 65°C. Viral DNA was extracted using phenol/chloroform and precipitated
with ethanol.

The DNA pellets were washed with 70% and dried.

DNA

concentration was determined spectrophotometerically (A260/A280).

PCR Amplification
The primers for the UL146 and UL147 ORFs were designed for conserved
regions

that

flank

each

of

the

ORFs.

The

primers

5’-

GTCATGGACGCAGTTTTG-3’ (forward) and 5’-GAACGATCTCGTCCGGTTC-3’
(reverse) were identical to those used in Arav-Boger et al [158]. The size of the
PCR

product

is

1.2-kb.

For

the

CGTATTACAAACCGCGGAGAGGAT-3’

UL144

ORF,

(forward)

the

primers
and

5’5’-

CTCAGACACGGTTCCGTAAAGTG-3’ (reverse), which are located upstream or
downstream of UL144 ORF, generate a 740-bp product. The PCR conditions for
UL146 and UL147 ORFs were 95ºC for 2 min, followed by 40 cycles of 95ºC for
30 sec, 55ºC for 30 sec, 72ºC for 2 min. The reaction was extended at 72ºC for
10 min. The UL144 PCR conditions were similar except the extension time was
reduced to 1min.
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DNA Sequencing
The amplicons were cloned into the pGEM-T Easy vector using the
pGEM-T Easy kit (Promega) according to the manufacturer’s instructions. At
least three colonies were picked and sequenced in both directions using
universal primers (SP6 and T7). For the serial isolates from VCU, if differences
were identified in the UL146 ORF, the entire PCR reaction was repeated to
ensure that any differences were due to differences in viral DNA and not due to a
PCR amplification error. All confirmed sequences were submitted to Genebank
(Accession

numbers:

UL146:

EU514891-EU514955;

UL147:

EU514794-

EU514845; UL144: EU514846-EU514890)

Phylogenetic Analysis
The sequenced ORFs were converted to amino acids using Vector NTI 9
(Invitrogen).

The predicted mature forms of vCXCL-1 and vCXCL-2 were

generated with Signal P (www.cbs.dtu.dk/services/SignalP). Alignments of the
mature forms of vCXCL-1, vCXCL-2, and UL144 proteins were aligned using
ClustalX 1.83.

Neighbor-joining phylogenetic trees were generated using

ClustalX 1.83 with 1000 bootstrap trials. The generated phylogenetic tree was
viewed by TreeView (Win32) 1.6.6.
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Statistical Analysis
Associations between genotype and whether any symptoms were
observed were analyzed using Fisher's exact test. For each individual clade, we
also calculated a 95% confidence interval for the proportion of asymptomatic
individuals. All analyses were performed using SAS v9.1.

Results
vCXCL-1s from children with congenital HCMV infection can be
divided into 11 distinct clades
To understand whether specific vCXCL-1s correlate with clinical outcomes,
51 samples were analyzed from 50 congenitally infected children (Table 2).
TX11 and TX12 were from same child. Using primers upstream and downstream
of the UL146 and UL147 genes [158] PCR products were obtained from the 51
clinical isolates. Each sample was PCR amplified twice, TA cloned, and two to
five clones were sequenced.

The accuracy rate was greater than 99.9%

between the two separate PCR reactions. For reference sequences, we included
the previously analyzed strains Toledo, Towne, C952, C954, C956, E760, ML1,
TB40/E, FS, AL, 6397, KM, RK, Davis, NT, Merlin, and KSG [155, 234] in
addition to the F strain from Prichard et al [26].

The UL146 ORFs encode

vCXCL-1 proteins containing between 115-121 amino acids. The mature forms
without the signal sequence and the reference sequences contain between 93
and 103 residues that show 5% identity (6 residues) and 8% similarity
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Table 2. Clinical isolates of congenital CMV infection
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(9 residues) (Fig. 2). All sequences were assigned to 11 distinct vCXCL-1 clades
(Fig. 3). The intravariability within each clade was less than 6%. The designated
genotypic group numbers were assigned according to the 14 UL146 groups
described by Dolan et al. [234]. No vCXCL-1 sequences were found in groups 3,
4, and 5 described by Dolan et al.
If the most distant reference group is removed (NT from Group 4, for
which we did not assign any samples), the number of 100% consensus residues
increases from 6 to 11. This includes the CXC chemokine motif and the four
cysteine residues. This implies that this isolate is a very distant cousin of other
vCXCL-1s. This number increases to 12 when all of the reference sequences
are removed from the analysis. These conserved residues provide the essential
structure for all α-chemokines [107]. The vCXCL-1 sequence of TX15 replaces
the glutamic acid-leucine-arginine (ELR) with asparagine-glycine-arginine (NGR)
motif, which is similar to the NRG containing chemokine found in the ML1 strain
[234] (Fig. 2). Modification of the ELR motif (E → N and L → G) could have
profound effects on chemokine function as the ELR motif is necessary for
chemokine activity and receptor binding [237, 238]. To further identify possible
functional differences that are reflected in their sequences, we clustered the
groups based on their N-loop regions. The N-loop region, the residues between
the second cysteine and the 310-helical turn (approximately 8-10 residues), is
responsible for receptor engagement and function [36, 106, 107]. Analysis of
these sequences divides the chemokines into the same 11 groups indicating that
the N-loop region is mainly responsible for vCXCL-1 variability (Fig. 4). There is
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Figure 2. Amino acid alignments of the mature forms of vCXCL-1s from
clinical isolates.
vCXCL-1 amino acid sequences from 51 clinical isolates were analyzed. Eighteen symptomatic
clinical isolates are indicated in bold. The vCXCL-1 sequences from reference strains Toledo,
Towne, C952, C954, C956, E760, ML1, TB40/E, FS, AL, 6397, KM, RK, Davis, NT, Merlin, and
KSG (GenBank accession numbers AY681092, AY681095, DQ115733, DQ115734, DQ115735,
DQ115754, AY446880, AY446866, AY446877, AY446887, AY446870, AY446893, AY446885, AY446868,
AY446890, AY446894, and AY446889, respectively) plus strain [F] from Prichard et al. (2001) are

boxed. The ELR motif and N-loop region, which are important in receptor binding and activation,
are indicated at the top. Residues that are 100% conserved are shaded black and residues that
are conserved in greater than 80% of the sequences are shaded in gray. Consensus sequences
with 100%, 90%, and 80% conservations are shown at the bottom.
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Figure 3. vCXCL-1 phylogenetic analysis.
The mature forms of vCXCL-1 from 51 clinical isolates with the reference
sequences (shaded gray) were assembled into a phylogenetic tree using
ClustalX. Eighteen symptomatic clinical isolates are indicated in bold. Bootstrap
numbers are shown. Group designations correspond to those used by Dolan et
al. (2004).
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Figure 4. Phylogenetic analysis for the N-loop region of vCXCL-1.
The N-loop regions of vCXCL-1 from 51 clinical isolates with the reference
sequences (in gray box) were analyzed using ClustalX. Eighteen symptomatic
clinical isolates are indicated in bold. Bootstrap numbers are shown. Group
designations correspond to those of the mature forms of UL146 amino acid (Fig.
2).
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0% similarity within this region between the different clades. The fact that there
is hypervariability within this region implies that these chemokines may have
different affinities for the chemokine receptors and could trigger different
downstream signaling and subsequent functions.

Differences in affinity,

apoptosis, and integrin expression have been noted for chimpanzee CMV
vCXCL-1 compared to vCXCL-1Tol [239].
The variability of vCXCL-1 does not show a definitive correlation between
specific vCXCL-1 sequences and HCMV sequelae. Overall, there was not a
statistically significant association between vCXCL-1 clades and symptoms at
birth (p=0.37).

However, examination of individual clades did reveal three

clades with an unusually high proportion of asymptomatic children. These were
group 8 with 7 of 8 (88%) asymptomatic (95% CI: 47% to 100%), group 10 with 3
of 3 (100%) asymptomatic (95% CI: 29% to 100%) and group 12 with 5 of 6
(83%) asymptomatic (95% CI: 36% to 100%).
One isolate, 300016, is assigned to two vCXCL-1 groups (group 1 and 13)
(Fig. 3).

After resequencing and analyzing 10 clones, these assignments still

held. This indicates this child was infected with two different HCMV isolates as
has been seen in both congenital infections and immune compromised patients
[27, 240, 241].

40

vCXCL-2 from children with congenital HCMV infection has limited
variability
The UL147 ORF from the same set of clinical isolates encodes vCXCL-2
proteins comprised of 157–167 amino acids (Fig. 5). In contrast to the vCXCL-1
protein the mature form of the vCXCL-2 from the clinical isolates were all
identical lengths (119 aa). The mature form of vCXCL-2 shows 87% identity (103
residues) and an additional 11% similarity (13 residues) overall. Because of the
limited variability of UL147 sequences from clinical isolates, the alignment of the
mature vCXCL-2 proteins falls into a single group. As previously published, the
only significant variability within vCXCL-2 occurs in the signal sequence [158],
which is cleaved during protein maturation.

UL144 sequences fall into three genotypes
UL144 is a member of the TNF receptor family [164]. Arav-Boger et al showed a
direct link between specific UL144 genotypes and clinical outcomes [156, 170]
while others have not [165-169, 242].

In order to establish whether specific

clades of UL144 are associated with clinical outcomes, 44 UL144 sequences
from the 51 clinical isolates were amplified and sequenced. We included the
sequences of genotypes A, B, C, AB, and AC (GenBank accession numbers
AF498086-AF498090) as reference sequences.

The UL144 ORF encodes a

protein of 175–176 amino acids. The UL144 mature form without the
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Figure 5. Alignment of the mature forms of vCXCL-2.
vCXCL-2 sequences from 51 clinical isolates were analyzed. 18 symptomatic
clinical isolates are indicated in bold. The reference strains Toledo and Towne
(GenBank accession # AY681092 and AY681095, respectively) were included
and are boxed. Residues that are 100% conserved are shaded black and
residues conserved in 80% to 99% of the sequences are shaded grey. The
consensus residues with 80% conservation are shown at the bottom.
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signal sequence is between 146–157 residues in length with 60% identity (95
residues) with an additional 27 similar residues (Fig. 6). These UL144 amino
acid sequences separate the isolates into five major genotypic groups (A, B, C,
and subgroup AB and AC) (Fig. 7). Previously, Lurain et al and Arav-Boger et al
reported the same groupings based on UL144 sequences [166, 170]. We used
the UL144 classification of Arav-Boger et al for this study. Bale et al showed
UL144 variability from 16 congenitally HCMV infected children [165]. They found
that clinical isolates TX11 and TX12, which were obtained from same child,
showed different UL144 group designations, group 3 (or B) and group 1 (or A).
Once again this indicates a child with multiple HCMV infections. Interestingly,
our results mapped the UL146 genotypes of these two isolates to the same clade
(group 11), which were confirmed by two separate PCR amplifications and
sequencing of five clones each (Fig. 3). This implies divergence within UL144
and that the two strains could have evolved under different environmental
pressures.
The UL144 protein consists of two cysteine-rich domains (CRD), one
transmembrane domain (tm), and one cytoplasmic domain (cyto). Unlike the
TNFR, UL144 lacks an additional CRD3 region which may explain absence of
binding to TNF-like ligands [164]. The alignments show that UL144 CRD1, which
is comprised of 34 residues, shows 50% identity (17 residues) and this
percentage increases to 71% when similar residues are included. The CRD2 is
slightly more conserved.

Of the 36-37 residues, there is 57% identity (21

residues) and 81% similarity. BTLA binds to the CRD1 of HVEM, which is
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Figure 6. UL144 contains highly conserved domains.
UL144 amino acid sequences from 44 clinical isolates were analyzed. 13
symptomatic clinical isolates are indicated in bold. Representative sequences
from genotype groupings A, B, C, AB, and AC (GenBank accession numbers
AF498086-AF498090) are included as reference sequences and are boxed.
Residues that are 100% conserved are shaded black and residues that are
greater than 80% conserved are shaded grey. Consensus sequence with 80%
conservation across all isolates are shown at the bottom. The cysteine rich
domains (CRD), the transmembrane region (tm), and cytoplasmic tail (cyto) are
indicated at the top.
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Figure 7. UL144 sequences fall into 5 groups.
The mature forms of UL144 amino acid sequences from 44 clinical isolates were
analyzed by the ClustalX. 13 symptomatic clinical isolates are indicated in bold.
Reference sequences are illustrated with grey boxes. Group designations
correspond to those of Arav-Boger et al (2002).
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homologous to UL144 CRD1 [236]. As observed in previous studies there is a
high level of conservation in the transmembrane and cytoplasmic domains of
UL144 between the different isolates [166, 170].

The variability in the CRD

regions has been used to infer that the interaction between UL144 and BTLA
could differ between the different genotypes, leading to differential virus survival
and/or clinical outcomes.
Using our clinical samples from congenitally infected children, we show
that the UL144 genotype does not correlate with HCMV sequelae. Using Fisher’s
exact test, there was no statistically significant association between UL144
genotype and symptoms (p-value = 0.45). Group B in our sample did have 18 of
23 (78%) asymptomatic (95% CI: 45% to 92%) while groups A and C had lower
percentages of asymptomatic newborns (Group A= 69% (9/13) and Group
C=40% (2/5)). This data indicates that there is no direct correlation between
UL144 genotypes and symptoms at birth, although the trend of more
asymptomatic children in group B is similar to the findings of Arav-Boger et al
[233].

UL146 genes under immune selection pressure do not mutate
One explanation for the variability in the UL146 gene is that UL146
evolves to avoid the immune response. To address whether the UL146 gene
accumulates mutations while under immune selection pressure, we studied serial
HCMV isolates from children who shed HCMV over many years [243].

We

cloned and sequenced the UL146 ORF from 13 serial isolates from six children
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from daycare centers in Virginia (Table 3). For up to three years, there was no
change in vCXCL-1 (Fig. 8). However, multiple UL146 sequences were identified
from sequential isolates from two individuals. In child 5, isolates 30135 and
31099 were assigned to group 9 and 8, and in child 6, isolates 23914 and 24864
were assigned to group 8 and 9, respectively. In order to confirm these isolates
resulted from multiple infections and not mutations of the original virus, we
sequenced the UL144 gene from these same isolates. The UL144 sequences
from isolates 23914 and 24864 were assigned to group A and B, respectively.
This data indicates these children were infected with two different viruses and
that the UL146 gene did not accumulate multiple mutations leading to
assignment to a new clade.

Discussion
There have been several studies addressing the effect of UL146 variation
on HCMV pathogenesis in immune compromised patients [155, 157-159, 233,
234]. The UL146 ORF is one of the most variable genes in the HCMV genomes
following analysis of isolates from AIDS or organ transplant patients [27, 244,
245]. These studies lead to the classification of UL146 sequences into 14 groups.
This variability, its role as a chemokine and its absence from lab attenuated
strains, lead to the hypothesis that this gene could encode a virulence factor.
Dolan et al, Hassan-Walker et al, and Arav-Boger et al investigated the link
between specific UL146 clades and symptomatic/asymptomatic congenital
infections [159, 233, 234]. Arav-Boger et al showed that from 21 clinical isolates
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Table 3. Serial isolates from Virginia Commonwealth University (VCU) day
care center

Isolate ID

Sampling Date

UL146
Genotype

24534

12/2/1997

8

27472

3/9/2000

8

27568
27716
29333

5/12/2000
7/12/2000
8/16/2001

10
10
10

26756

8/25/1999

11

29524

10/10/2001

11

4

29140
30803

6/25/2001
2/20/2003

7
7

5

23914
24864

2/25/1997
4/1/1998

8
9

30135

4/25/2002

9

31099

6/19/2003

8

child No.
1

2

3

6
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Figure 8. vCXCL-1 does not mutate in long term shedders.
vCXCL-1 from 13 serial isolates from 6 children for up to 3 years were analyzed.
A) The alignments shown are from individual children over a span of one to three
years. Residues that are 100% conserved are shaded black and grey regions
residues indicate conservative substitutions. B) ClustalX was used for
phylogenetic analysis of the different isolates.
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no specific UL146 genotype was associated with disease outcome [233].
Hassan-Walker et al and Dolan et al showed 4 and 14 genetic groups,
respectively. However, due to the small sample size (14 and 7, respectively)
they could not draw a direct link between genotypes and symptoms [159, 234].
Even though our study includes a relatively large sample size, we are
unable to reach statistically significant conclusions about specific UL146 clades
and symptomatic outcomes. Our results demonstrate that out of the 14 groups,
11 of the clades did not exhibit a definitive association between UL146
genotypes and symptoms. Group 10 contained only asymptomatic children but
had a sample size of 3. In group 8, only 1 out of 8 were symptomatic. From this
data we can conclude that most of the UL146 genotypes do not correlate with
symptomatic births and two of these groups (Group 8 and 10) point towards
asymptomatic outcomes but a statistically significant conclusion is limited
because of sample size.
The other gene located within the UL/b’ region, which has homology to the
TNF receptor and is variable is UL144. Our UL144 data in this study shows a
lack of correlation between symptoms and UL144 clades supporting the findings
of several other studies [156, 165-170, 242]. Only Arav-Boger concluded that
UL144 is predictive of congenital infection outcomes [156, 170]. The major
differences between these studies are the sample size and the source of the
isolates. Arav-Boger et al suggested that groups A and C are associated with
more serious outcomes upon analysis of 23 congenitally infected isolates
comprised of 13 symptomatic neonates and fetuses.
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The B genotype was

associated with both asymptomatic (10 out of 10) and symptomatic (6 out of 13)
children and the A and C genotypes were only found in the symptomatic children
[170]. From this, they concluded that the A and C genotypes are associated with
symptomatic outcomes. This group also showed a possible relationship between
the C genotype and symptomatic diseases in newborns in a study in Italy. They
showed a statistically significant association between the C genotype and
termination of pregnancy, while the B genotype did not [156]. This study did
suffer from enrollment biases as women were enrolled based on a higher risk for
congenital CMV infections. In contrast, Bale et al examined 51 HCMV isolates
from 44 patients containing 16 congenitally infected children to conclude that
UL144 genotype does not correlate with symptoms at birth [165]. Others have
corroborated the Bale study.

Mao et al analyzed 70 isolates from Chinese

infants where 58 were from symptomatic children, but only five infants were
determined to have acquired CMV from congenital infections [167]. An even
larger Japanese study assessed the UL144 sequences from 74 Japanese HCMV
isolates where 10 samples were from congenitally infected newborns [168].
They also reported that UL144 genotype does not correlate with symptoms.
Analyzing HCMV congenitally infected fetuses, Picone et al concluded that there
was no correlation between severity of infection and UL144 genotype [242]. All
of these studies divided the UL144 genotypes into three major groups: 1, 2, and
3 (or A, C, and B, respectively) and did not find a statistically significant
relationship between these genetic groups and specific clinical symptoms at birth.
In our study, 23 of 44 samples had the B UL144 genotype. Of these, 5 of 23
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infants were symptomatic while 18 were asymptomatic. In contrast to the study
of Arav-Boger, we observed that both A and C clades contain both asymptomatic
and symptomatic children (Fig. 7).

Therefore, our analysis of the UL144

sequences agrees with previous findings of Bale et al.
Because of its high variability, UL146 sequences can be used as an
indicator of multiple HCMV infections. Multiple HCMV infections could be due to
either incomplete protection after HCMV infection or coinfection simultaneously
with different strains of HCMV. Multiple infections have been found in both
congenitally infected patients [233], renal transplant patients [155], bone marrow
transplant patients [155], and AIDS patients [234]. In immunocompetent children,
Bale et al studied 11 serial isolates from five children for up to 2.5 years and
found multiple sequences [165]. Based on the genetic stability of UL146
sequence over time, multiple sequences are not due to random mutations.
Therefore the multiple sequences were due to coinfection with another strain of
HCMV. We have also found multiple sequences from children in daycare (Fig.
8A) indicating that coinfections with multiple strains of HCMV are possible.
Since UL146 and UL144 genes are variable, many studies have
addressed the stability of UL146 or UL144 genotype upon serial isolation over
many years [155, 157, 159, 168, 170, 234].

Lurain et al studied various organ

transplant recipients for up to 5 years with no changes in UL146 sequence [155].
Both in vitro [155] and in immune compromised hosts, UL146 did not mutate over
time [159]. A possible explanation of UL146 and UL144 hypervariability could be
due to immune selection pressure within the host. Our study (Fig. 8) and Bale et
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al analyzed immunocompetent children shedding virus over many years. This
would have allowed for vigorous immune selection compared to the
transplantation studies where the host is immune suppressed and are often
treated with anti-CMV drugs.

Immune selection could select for mutated,

secreted vCXCL-1 protein that is recognized as foreign, because it is only ~2030% homologous to host chemokines.

Interestingly, Lurain et al showed no

variation in UL146 sequences even when different patients received organs from
the same donor. These organs contained the same strain of HCMV as the donor
but were transplanted into different hosts, which could mount different immune
responses [155]. This shows the stability of UL146 over time and in different
immunological settings from different individuals.
Most immune competent individuals shed HCMV for about 9-12 months
after acquisition. In contrast, primary CMV infection of neonates and infants
results in continuous viral shedding into the urine and saliva for several years
[246-248]. Our data are unique in that our samples were isolated from healthy
children (i.e. not immunocompromised).

If immune selection drives UL146

variation, our analysis should identify it. Our data from healthy children also
agrees with the studies from immunocompromised patients. We found 2 cases of
coinfection, which fell into group 8 and 9, but no sequence changes were
detected during two years, indicating that virus maintains its genetic integrity
under healthy immune defense. If mutations are not occurring in this time frame,
how and why are these genes so variable? One possibility is that changes in the
genes accumulated during HCMVs’ co-evolution with humans.
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The gradual

changes in UL146 and UL144 provide an evolutionary advantage, which only
becomes dominant over millennia.
In conclusion, this study shows that specific UL146 and UL144 genotypes
do not correlate with the sequelae of congenital infection. We also show that
some children in daycare are infected with multiple strains of HCMV and that
their HCMV UL146 genotypes do not change over several years.
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Chapter 4
POLYMORPHISMS IN HCMV VIRAL CHEMOKINE, VCXCL-1,
ELICIT DIFFERENTIAL ACTIVATION

Abstract
The human cytomegalovirus (HCMV) UL146-encoded viral chemokine,
vCXCL-1, is hypervariable.

In our previous analysis of clinical isolates from

congenitally infected infants, we found 11 distinct vCXCL-1 genotypic clades. In
these clades, the N-loop region, which is important for receptor-binding varied.
One isolate also contained a modified ELR motif, which is vital for binding to
CXCR1 and CXCR2 receptors.

In this study, we produced and purified

representative vCXCL-1 proteins from each of the 11 clades using a baculovirus
protein expression system. We measured vCXCL-1’s affinity for either CXCR1 or
CXCR2 using competition binding assays. All vCXCL-1s bound to CXCR2 albeit
with different affinities. Interestingly, we found a trend that vCXCL-1s with high
affinity for CXCR2 receptors also bind CXCR1. We also examined functional
differences between the vCXCL-1s using chemotaxis, integrin activation, and
calcium mobilization assays on human neutrophils. All vCXCL-1s were able to
activate human neutrophils. However, the potency of the vCXCL-1s to induce
chemotaxis of neutrophils varied. Moreover, the vCXCL-1s varied in their ability
to induce CCL22 production, which did not correlate with chemotaxis potencies.
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Our data suggest that the vCXCL-1 polymorphisms elicit different binding
affinities, receptor usage, and differential cellular activation, which potentially
contribute to HCMV pathogenesis.

Introduction
Human cytomegalovirus (HCMV) is a ubiquitous pathogen that is well
adapted to modulate host immune responses [113, 249]. HCMV contains genes
for immune evasion that could function to increase viral survival, dissemination,
or may contribute to pathogenesis [143, 250, 251]. There are a large number of
open reading frames (~62) called the UL/b’ region in HCMV that are nonessential for virus replication in vitro but may have a role in immune evasion in
vivo [25, 245]. Among the UL/b’ open reading frames (ORFs), UL146 and UL147
genes have limited homology to CXC chemokines [25]. The UL146 ORF from
the Toledo strain of HCMV called vCXCL-1Tol has been shown to produce a
functional CXC chemokine [143].

vCXCL-1Tol binds to CXCR1 and CXCR2,

induces neutrophil chemotaxis and calcium mobilization [154].

These data

suggest that vCXCL-1s produced from CMV-infected endothelial cells recruit
neutrophils and contribute to viral dissemination [143, 252]. Sequencing of the
HCMV genomes and the UL146 gene from numerous clinical isolates [27, 240,
241, 244, 245, 253] showed that the UL146 gene is one of the most variable
genes in the entire HCMV genome [27].
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vCXCL-1s are members of the chemokine family. Chemokines are small
chemoattractant cytokines between 70-130 amino acids in length. The two major
families of chemokines (CC and CXC) contain four conserved cysteine residues
that contribute to the overall structure. Whether an amino acid separates the
amino terminal cysteines is used for dividing chemokines into the CXC or CC
families. The N-terminus preceding the first cysteine is an important region for
receptor binding and activation [30, 96]. The Glu-Leu-Arg (ELR) motif found in
CXC chemokines is a critical motif for CXCR1 and/or CXCR2 receptor
recognition and activation [102, 103]. Introduction of an ELR motif into the nonELR CXC chemokine CXCL4 (PF4) converted it into a neutrophil attractant and
activator [34], although another non-ELR CXC chemokine, CXCL10 (IP-10),
required additional modifications to become a fully functional protein on human
neutrophils [104].

Following the second cysteine is a flexible N-loop of

approximately ten residues. The N-loop is responsible for receptor engagement
and function [30, 35, 96, 104]. Skelton et al. showed that CXCL8 and CXCR1 Nterminus fragment, CXCR1-p1, interact along the ELR and N-loop motifs of
CXCL8 [105]. Further, Lowman et al. demonstrated that CXCL1 (Gro-α) could be
altered to bind both CXCR1 and CXCR2 when the N-loop region of CXCL8 (IL-8)
was swapped into CXCL1 [96].

These data indicate that the ELR motif is

necessary for receptor recognition and the N-loop region controls specificity for
CXCR1 over CXCR2.
Previously, we sequenced the UL146 gene from congenitally HCMV
infected clinical isolates [160]. We found 11 clades of vCXCL-1 including one
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non-ELR CXC chemokine, vCXCL-1TX15. Furthermore, analysis of the N-loop
divides the chemokines into the same 11 clades, indicating that the N-loop region
is mainly responsible for vCXCL-1 variability [160].

Although the genetic

variability of vCXCL-1 did not show a definite correlation with clinical symptoms,
this hypervariability within the N-loop region suggests that these chemokines
may have different affinities, receptor usage, and trigger different downstream
signaling and functions.

For example, eotaxin (CCL11) induces eosinophil

migration exclusively via CCR3. CCR3 is known to be a promiscuous chemokine
receptor, responsive to more than a dozen different ligands [254, 255]. Eotaxin-2
and eotaxin-3 bear less than 40% identity to eotaxin at the amino acid level (i.e.
eotaxin vs. eotaxin-2 (39%); eotaxin-2 vs. eotaxin-3 (33%)), yet they also bind
and function through CCR3. While eotaxin and eotaxin-2 bound equally, eotaxin3 showed ~10-fold lower affinity than eotaxin [256]. Eotaxin-3 was less potent
than eotaxin in eosinophil chemotaxis [257] while eotaxin-2 showed a similar
potency to eotaxin [258]. In order to address functional variability of the vCXCL1s, we generated recombinant vCXCL-1s from each clade and performed
competition-binding assays and functional assays to assess how vCXCL-1
variability affects function.

Materials and methods
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Cells and clinical isolates
Insect cells SF9 were purchased from Gibco and Hi5 cellls from Cellgro.
HEK293 cells were a gift from Dr. Cynthia Peterson’s lab (University of
Tennessee).

Human myelomonocytic HL-60 T2 cell transfectants over-

expressing CXCR2 were a gift from Dr. Ann Richmond (Vanderbilt University).
The 51 clinical isolates were provided by Dr. James Bale (University of Utah
School of Medicine) and Dr. Gail J. Demmler (Texas Children's Hospital) as
described previously [160].

Neutrophil isolation
Peripheral blood neutrophils (PBN) were isolated from EDTA-treated
blood from healthy human volunteers using dextran sedimentation and density
gradient centrifugation as previously described [259].
removed with hypotonic lysis in 0.2% NaCl.

Erythrocytes were

After removal neutrophils were

resuspended in the buffers for the individual assays. Viable neutrophils were
quantified with trypan blue exclusion using a hemacytometer. The use of human
subjects has been approved by the University of Tennessee Institutional Review
Board (IRB# 6476B).

Production of recombinant vCXCL-1s
The vCXCL-1 gene, UL146, was PCR amplified from HCMV DNA of each
of the 11 clades from a representative clinical isolate and cloned into the
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baculovirus transfer plasmid 1392 (Invitrogen), which contains homologous
regions for recombination into the baculovirus genome.

PCR primers were

designed to include the open reading frame (ORF) and included an additional 2-4
glycines and six histidines on the carboxyl terminus of the proteins for
purification. For the generation of baculoviruses, SF9 cells were transfected with
the 1392/UL146 ORF plasmid construct and Sapphire linearized baculovirus
DNA (Orbigen) according to the manufacturer’s instructions.

Recombinant

baculovirus containing the UL146 gene was titrated and used to infect Hi5 cells
for optimum protein expression. 48 hrs after infection, cells and supernatants
were harvested.

Recombinant proteins were isolated from the supernatants

using Ni-NTA agarose beads (Qiagen) and resuspended in PBS.

Protein

concentration was quantified using Coomassie blue staining of SDS-PAGE gel
using lysozyme as a standard. Quantity One software (Bio-Rad) was used for
protein quantification.

Receptor binding analysis
The ability of vCXCL-1s to compete for binding to either CXCR1 or
CXCR2 was evaluated as previously described [143]. Briefly, 1-3x105 HEK293
cells over-expressing CXCR1 or CXCR2 were incubated with 0.2nM
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I-labeled

CXCL8 (Perkin Elmer) and increasing concentrations of unlabeled chemokines.
Cells were collected via a 96-well 0.45 mm Durapore membrane (Millipore) filter
format on a vacuum manifold, washed twice, and bound radioactivity was
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measured with liquid scintillation counting. The competition curves were plotted
and 50% effective concentration (EC50) were determined using GraphPad Prism.

Intracellular calcium mobilization assays
Release of calcium from intracellular stores was determined on freshly
isolated PBN resuspended in PBS. Cells were loaded with 3 µg/ml Indo-1-AM
(Molecular Probes) for 60 min at 37 °C. Cells were washed with PBS and diluted
to 1×106 cells/ml in Hanks' balanced salt solution (HBSS) containing Ca2+ and
Mg2+ and 1% FBS (Hyclone). Chemokines were added to 2 ml of cells at a final
concentration of 100 nM. All host chemokines were purchased from Peprotech
(Rocky Hill, NJ) and endotoxin levels were less than 0.1 ng per µg (1 EU/µg).
Calcium flux was measured using a Photon Technology International
Spectrophotometer (New Jersey) at an excitation of 350 nm and FeliX32
software for analysis. Relative intracellular calcium levels were expressed as the
ratio of emissions at 490 nm / 400 nm.

β2 integrins staining
1×106 PBN cells were resuspended in RPMI-1640 (Biowhittaker) with 1%
FBS and exposed to 100 nM of chemokines for 2 h at 37 °C. Cells were washed
with PBS and blocked with 1% goat serum.

PBN were incubated with

fluorescently conjugated CD11a, CD11b, and CD11c antibodies (Caltag) on ice
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for 30 min. and fixed with 4% paraformaldehyde. Cells were analyzed with flow
cytometry (FacsCalibur, BD Bioscience).

Human PBN chemotaxis assays
Chemotaxis assays were performed on freshly isolated human PBN
resuspended in HBSS with 0.1% BSA and 10 mM HEPES.

Assays were

performed in triplicate in 96-well chemotaxis plates. 20 µl of chemokines were
loaded at varying concentrations (0, 1, 10, 100, and 500 nM) into the lower well
of the modified Boyden chamber (Neuroprobe) fitted with a 5 µm filter. 1×106
PBN in 30 µl were added to the upper well. The cells were incubated for 3 h at
37 °C. Migration of PBN was measured by direct counting of migrated cells into
the lower chamber. The chemotactic index was calculated as the number of
migrated cells in the presence of chemokine divided by the number of migrated
cells with buffer only.

Quantitative real-time PCR of CCL22 expression
HL-60 T2 cells over-expressing CXCR2 were differentiated for 7 days with
1.3% DMSO prior to chemokine treatment. Media was exchanged to HBSS and
incubated with viral chemokines at a final concentration of 100 nM for 4 h at 37
°C. Total RNA was isolated with Tri-Reagent (Sigma) and reverse transcribed by
the ProtoScript M-MuLV first strand cDNA synthesis kit (NEB). Real-time PCR
was performed using iQ5 Real-Time PCR Detection System (Bio-Rad) with a
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reaction mixture volume of 25 µl containing SYBR green (NEB DyNAmo SYBR
green qPCR kit), 300 nM of each primer, and ~25ug of cDNA.

Primers for

CCL22 were purchased from SABiosciences (Cat # PPH00697E). The reaction
conditions were 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C
for 60 s.

Data analysis used iQ5 Optical System Software (Bio-Rad).

The

relative gene expression levels were calculated as fold changes using the
formula Ratio = 2−ΔΔCT, where ΔCTtarget or

reference

= threshold cycle (CT) of the

control gene (ACT1) − CT of the target gene (CCL22), and ΔΔCT = ΔCTreference −
ΔCTtarget [260]. The housekeeping gene encoding actin (ACT1) was used as a
reference control.

Results
Amino acid sequence alignment
Previously we sequenced the UL146 gene from 51 clinical isolates and
showed that it comprised 11 genetic clades [160].

From 11 clades,

representative isolates were selected and aligned with vCXCL1 from the Toledo
strain (Fig. 9A). The percent identities of the vCXCL-1s ranged from 23.7 –
61.2% with 11 conserved amino acids: including the R of ELR motif, the four
cysteines, a glycine at position 21, two prolines at positions 32 and 87, a leucine
at position 56, a histidine at position 60, and a tryptophan at position 65 (Fig. 9A).
The Gly21 generates a single-turn 310 helix that finishes the N-loop region. The
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Figure 9. Amino acid alignment and recombinant vCXCL-1 production.
(A) Amino acid alignment of the mature forms of vCXCL-1s and host chemokines
(CXCL1 and CXCL8). Seven amino acids are conserved including four cysteines.
The ELR motif is conserved except for vCXCL-1TX15. The variable N-loop region
is located after second cysteine. (B) Recombinant vCXCL-1s production in
baculovirus protein expression system. 6His-tagged protein eluted from nickel
beads was run on a 15% SDS PAGE gel and stained with Coomassie blue.
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Pro32 is located in the 30s-loop between the β1-sheet and β2-sheet. Previously,
the Gly31-Pro32 motif in CXCL8 was shown to be essential for determining the
structure of the 30-35 region and possibly the 5-35 disulfide bond [29, 97, 104].
The Trp65 and Pro87 are in the C-terminal α-helix, which is followed by His60.
Furthermore, Leu25 and Val27 in CXCL8 that creates a hydrophobic
environment for dimer formation was not conserved in the vCXCL-1s [261, 262].
Also, mutation of Leu25 to tyrosine introduces monocyte chemoattractant activity
into CXCL8 [263].

Therefore, different β1-sheet amino acid formation can

possibly contribute to determining cell type selectivity via selective chemokine
receptor binding.
The mature forms of the viral chemokines, without the signal sequences,
contain between 93-98 residues; whereas human chemokines, such as CXCL1
(Gro-α) or CXCL8 (IL-8), contain 70-71 residues. What affect these additional 20
residues of vCXCL-1s have on function is unknown.

However, it has been

shown that glycosaminoglycans (GAGs) can bind to the C-terminal α-helix of
CXCL8 enhancing chemokine activity on neutrophils [264]. When vCXCL-1s are
compared to human chemokines, the scope of the percent identities was lowered
to 16.8% with 7 conserved residues: including the R of ELR motif, the four
cysteines, a proline at position 32, and a leucine at position 56. The ELR motif
was conserved except vCXCL-1TX15 which replaces ELR with an Asn-Gly-Arg
(NGR) motif. Single amino acid substitutions in this motif showed that all three
residues are sensitive to modification although the arginine is critically important
for CXCL8 function [34, 35]. Therefore, the modified ELR motif of vCXCL-1TX15
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could have profound effects on chemokine function or receptor binding [102,
103].

The variable N-loop region that is mainly responsible for vCXCL-1

variability is followed by the second cysteine [160]. Taken together, from the
high degree of variability in the N-loop, C-terminus, and even the ELR motif, we
hypothesized that there would be differences in function and even receptor
usage based on the modified ELR motif.

vCXCL-1 production using the baculovirus expression system
In order to address functional differences between the vCXCL-1s, we
generated recombinant vCXCL-1s using the baculovirus protein expression
system. Baculovirus expression provides mammalian signal-sequence cleavage,
generates eukaryotic glycosylation patterns and protein folding. vCXCL-1s were
6 His-tagged and purified using Ni-NTA agarose beads. A Coomassie blue stain
of the isolated proteins is shown in Fig. 9B.

The sizes ranged from

approximately 11 kDa to 15 kDa. The actual molecular weights of vCXCL-1s
were confirmed by Matrix-assisted laser desorption/ionization (MALDI) (Table 4).

vCXCL-1s vary in their affinities for CXCR1 or CXCR2
The conserved ELR motif suggests that the viral chemokines bind to
CXCR1 and/or CXCR2. However, the hypervariable N-loop binding region of the
vCXCL1s and non-ELR motif of vCXCL-1TX15 could result in differences in
receptor binding affinity. To test this possibility, competition-binding assays were
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Table 4. Molecular weight of vCXCL-1s by Matrix-assisted laser
desorption/ionization (MALDI) analysis
Chemokine

MW by MALDI

Toledo
E760
TX15
Towne
C954
102410
100751
TX11
TX24
C956
C952

14137
11077
12032
11960
11961
11880
11853
11157
13036
12912
11959
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used to evaluate the ability of vCXCL-1s to compete for binding to human
CXCR1 and/or CXCR2. All vCXCL-1s were able to compete with [125I]-CXCL8
for binding to CXCR2. 50% effective concentrations (EC50) of vCXCL-1s were
higher than CXCL8 (EC50 = 1.1 nM) (Fig. 10A). This indicates that most vCXCL1s bind to CXCR2 with a lower affinity than CXCL8. Among them, three vCXCL1s showed a high level of affinity for CXCR2 (vCXCL-1C952 EC50 = 3.5 nM,
vCXCL-1E760 EC50 = 3.8 nM, and vCXCL-1Tol EC50 = 5.1 nM). Interestingly, the
non-ELR CXC chemokine, vCXCL-1TX15, still bound to CXCR2 albeit with very
reduced affinity (EC50 > 131.4 nM). We also examined vCXCL-1 binding affinity
to CXCR1 to evaluate an idea of whether these chemokines mimic CXCL1,
which binds only to CXCR2, or CXCL8, which binds to both CXCR1 and CXCR2
(Fig. 10B). Although the binding affinities were very low, those with high affinity
binding to CXCR2 also showed binding to CXCR1 while the others demonstrated
no binding (vCXCL-1Tol EC50 > 46.7 nM, vCXCL-1C952 EC50 > 97.7 nM, vCXCL1E760 EC50 > 143.3 nM). This points to a trend that vCXCL-1s with high affinity to
CXCR2 receptors can also bind CXCR1.

vCXCL-1s stimulate calcium release in human PBN
Release of intracellular calcium is a common indicator of chemokine
activation of PBNs [143, 144]. vCXCL-1s were added to 2 ml of freshly isolated
human PBN to a final concentration of 100 nM. All vCXCL-1s showed similar
activation potential (Fig. 11) demonstrating that recombinant vCXCL-1s are
capable of inducing cellular activation of human PBNs and any differences in
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Figure 10. vCXCL-1s display variable affinities for CXCR1 and CXCR2.
(A) vCXCL-1s bind to CXCR2 with varying affinities. Representative vCXCL-1s
are shown. HEK293 cells stably expressing only CXCR2 were incubated with a
constant amount (0.2nM) of [125I]-CXCL8 and increasing amounts of unlabeled
chemokines as cold competitor. (B) Three vCXCL-1s bound to CXCR1 with
various binding affinities whereas other vCXCL-1s did not bind (>1000). (C) The
table summarizes the calculated EC50 values of all vCXCL-1s binding to CXCR1
and CXCR2 (nanomolar (nM)). vCXCL-1s that do not displace greater then 90%
of total counts are indicated with a > sign; therefore we are unable to calculate
accurate EC50 values with confidence. The data was analyzed in Prism 4.0. This
is combined data of three experiments.
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Figure 11. vCXCL-1s, regardless of affinity, mobilize intracellular calcium.
Recombinant vCXCL-1s have similar activation thresholds as host chemokines.
Changes in fluorescence were measured over time after exposure of human
PBN to 100nM of vCXCL-1s. Arrows indicate the time of addition of the
chemokine. Data is representative of three experiments.
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CXCR2 affinities do not affect calcium mobilization. Interestingly, 500 nM of the
non-ELR CXC chemokine, vCXCL-1TX15, did not show calcium mobilization in the
presence of 1 uM the CXCR2-specific inhibitor SB225002 while reduced
activation was observed when 100 nM CXCL8 was treated in the presence of the
inhibitor. This data indicates that even though vCXCL-1TX15 has a non-ELR CXC
motif, it still activates PBNs exclusively through CXCR2 (data not shown).

vCXCL-1s upregulate CD11b and CD11c on the surface of PBN
β2 integrins consist of an α component, such as CD11a, CD11b, and
CD11c, and a β component, CD18. They are present on circulating leukocytes
and mediate leukocyte adhesion and transmigration across the endothelium
[265]. Previous studies demonstrated the ability of CXCL8 to upregulate CD11b
expression [266]. Moreover, vCXCL-1Tol and a viral chemokine from chimpanzee
CMV (vCXCL-1CCMV) also increased CD11b and CD11c expression on the cell
surface of PBNs [144]. We tested the ability of vCXCL-1s stimulation to alter
surface expression of these receptors on PBNs. Exposure of human PBNs to
vCXCL-1s resulted in no change in the level of CD11a expressed on the cell
surface (Fig. 12). However, CD11b and CD11c levels increased upon exposure
to vCXCL-1s. The percent changes in the mean fluorescent intensity of CD11b
were 57-91.2 %, which were similar to CXCL1 (82.4 %) but less than CXCL8
(142.6 %). Likewise, the percent changes of CD11c were 34.9-55.3 %, which
were similar to CXCL1 (42.8 %) but still less than CXCL8 (80.3 %).

These

results imply that the viral chemokines selectively induce adhesion molecule
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Figure 12. vCXCL-1s differentially increase β2 integrin expression on the
surface of neutrophils.
(A) Human PBN were incubated in the presence of 100 nM of different vCXCL-1s
and labeled with fluorescently-conjugated antibodies against CD11a, CD11b, and
CD11c. Representative vCXCL-1s are shown. The shaded curve represents
expression levels of unstimulated neutrophils. (B) The table summarizes the flow
cytometry data and is expressed as percent change in the mean fluorescent
intensity compared to non-stimulated PBNs. This is representative experiment of
three experiments.
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upregulation, but there were no significant differences in expression levels
between different viral chemokines.

vCXCL-1s induce differential migration of human PBN
CXCL8 and vCXCL-1Tol are potent chemoattractants of neutrophils [102,
143]. The ability of the HCMVs to alter PBN migration could have a profound
effect on HCMV dissemination and subsequent pathogenesis.

In order to

address whether vCXCL-1 variation results in chemotaxis of PBNs, each
chemokine was used as a chemoattractant in a modified Boyden chamber assay.
vCXCL-1s showed different potencies in induction of neutrophil migration (Fig.
13). We categorized chemokines as low, intermediate and high responders
based on a ten-fold increase above random migration. vCXCL-1C954 showed the
highest chemotactic index among vCXCL-1s while the non-ELR CXC chemokine,
vCXCL-1TX15, was a low responder. Interestingly, the differences in potency of
neutrophil migration did not correlate with the differences in affinity for CXCR2 or
CXCR1 binding (Fig. 10).

vCXCL-1s differentially induce secondary chemokine production
(CCL22)
In order to examine secondary effects of vCXCL-1 exposure, the neutrophil-like
cell line, HL60T2, was stimulated with vCXCL-1Tol, host human chemokine
CXCL1, or PBS control and the change in transcription levels were measured
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Figure 13. vCXCL-1s induce variable chemotaxis patterns of human
neutrophils.
Chemotaxis assays were performed by loading neutrophils into the upper
chamber of a 96-well plate fitted with a 5 µm filter with increasing amounts of
chemokine loaded in the lower chamber (1, 10, 100, and 500nM). Results are
reported as a chemotactic index of the number of cells migrated divided by the
random migration ±S.D. Low responders are 20 fold greater than background.
Intermediate responders are 20-200 fold greater. High responders are more than
200 fold greater. Data is representative from 10 experiments.

74

using Affymetrix whole human genome array. One of the genes that was up
regulated upon exposure to either host or viral chemokines was CCL22
(macrophage derived chemokine (MDC) (data not shown)). CCL22 recruits
multiple immune cells, such as monocytes, dendritic cells, NK cells, and the Th2
subset of T cells [267]. Because HCMV can productively infect macrophages
and dendritic cells and an increase in Th2 responses will down-regulate Th1
responses, inducing CCL22 could increase HCMV dissemination while
diminishing CTL responses [118, 119]. We measured mRNA expression levels
of CCL22 upon exposure to the different vCXCL-1s (Fig. 14). We found that
vCXCL-1s differentially induce CCL22 production in vitro. For example, vCXCL1Tol showed the highest induction of CCL22 similar to or slightly higher than host
CXCL1, whereas the strains of Towne, TX15, 100751, 102410, and C954 did not
induce CCL22 expression. Interestingly, CCL22 induction correlated with affinity,
unlike calcium flux or integrin expression (Fig. 10). vCXCL-1C952, vCXCL-1E760,
and vCXCL-1Tol showed high affinity for CXCR2 and the highest CCL22
production.
profiles.

These patterns, however, do not correlate with their chemotaxis

This shows the complexity of signaling for the different phenotypic

readouts following chemokine exposure and how these chemokines can
functionally select different pathways.

Discussion
In order to investigate the relationship between the hypervariable vCXCL-1s and
clinical outcomes, we previously cloned and analyzed UL146 ORF from
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Figure 14. Secondary chemokine production (CCL22) various upon vCXCL1 stimulation.
Neutrophil-like HL-60 T2 cells over-expressing CXCR2 were incubated in the
presence of 100 nM of different vCXCL-1s. Total RNA was extracted and reverse
transcribed for real time RT-PCR. A ratio of 1, indicated with a dashed line,
means no change in expression compared to the negative control with no
chemokine treatment. This is representative data from three experiments
using separately stimulated HL-60 T2s each time.
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congenitally CMV infected children [160]. We did not find a statistical correlation
between a specific UL146 genotype and congenital infection outcome, which
perhaps was due to the limited sample size. However there were specific clades
that showed a tendency toward asymptomatic outcomes. This led us to the
current investigation of chemokine function to address whether specific vCXCL-1
clades have distinct functions or at least different levels of activation. Alignment
of the mature vCXCL-1s showed the highly conserved ELR motif and placement
of the conserved cysteines, whereas the N-loop region was hypervariable with
very little homology (Fig. 9).

Structure-function studies on chemokine and

chemokine receptor interactions have suggested a two-site binding model [101,
268, 269].

This model introduces two interaction sites: the N-loop of the

chemokine to the N-terminus of receptor (Site-I) and the N-terminus including
the ELR motif to the extracellular/transmembrane part of the receptor (Site-II).
Site-I binding serves as an initial docking step, and then Site-II interaction
induces conformational changes in receptor transmembrane helices that allow
signaling of cellular function [270].

We have shown that two additional viral

chemokines (vCXCL-1C952 and vCXCL-1E760) bind to CXCR1 and this correlated
with high affinity binding to CXCR2. The evolutionary advantage of binding to
CXCR1 could be an induction of neutrophilic responses, such as increased
chemotaxis, cytokine production or ”functionally selective” cellular responses.
There are two nonexclusive models for the role of viral chemokines in
HCMV dissemination. One model is the neutrophil shuttle model. This model
proposes that the neutrophil is the main vehicle for HCMV dissemination [271]. It
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has been reported that HCMV abortively infects neutrophils during neutrophil
transendothelial migration across infected endothelium and subsequently
transmits HCMV to fibroblasts [252, 272]. This would allow HCMV to infect the
surrounding tissues or different cell types. The guinea pig CMV (GPCMV) MIP
homolog functions through the CCR1 receptor and appears to play a role in viral
dissemination in vivo [149, 273]. Furthermore, viral-related inflammation also
likely contributes to cytomegalovirus-related inner ear injury (auditory pathology)
[274]. We analyzed the cell activation level and induction of adhesion molecules
upon vCXCL-1 treatment, which could affect neutrophil diapedesis from the
vasculature and subsequent cell-mediated viral dissemination.

In this study,

although the binding affinities to CXCR2 and/or CXCR1 were variable, all
vCXCL-1s were capable of inducing intracellular calcium mobilization in PBNs
(Fig. 11) and upregulating β2 integrins on the surface of PBNs to similar levels to
human CXCL1 (Fig. 12). Chemotaxis of circulating neutrophils is dependent on
adhesion to and extravasation across the endothelium. Therefore, we conclude
that vCXCL-1s increase PBN contact with the endothelium and could then use
PBN as a vehicle for dissemination. Interestingly, albeit all tested vCXCL-1s
showed similar activation patterns in both calcium flux and β2 integrin assays,
they have different potencies to recruit human PBN (Fig. 13). This response was
independent of receptor binding affinity. For example, vCXCL-1C952 has high
affinity but low chemotaxis and vCXCL-1C954 showed low affinity but high
chemotaxis. This leads us to conclude that different receptor binding affinities do
not directly correlate with subsequent PBN activation, integrin upregulation or
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chemotaxis pattern.

This has recently been shown in a mutagenic study of

CXCL8 where mutations of the CXC motif diminished affinity while not affecting
function [268].
Another model for the relationship between the viral chemokine and
neutrophil is the neutrophil amplifier model. The focus of this model is more of
the downstream effects of neutrophil activation.

This model proposes that

vCXCL-1 leads to exocytosis of neutrophilic granules or induces expression of
specific cytokines or chemokines that then affect the next wave of the
inflammatory response that would then contribute to HCMV dissemination. For
example, macrophages and dendritic cells would provide better targets for HCMV
because HCMV can productively infect these cells [275-277] while infection of
PBNs is abortive [272].

Moreover, HCMV infection promotes monocyte-to-

macrophage differentiation as a strategy to promote viral replication [277]. At the
same time, secretion of chemokines or cytokines from the infiltrating cells could
also alter the immune response.

This has been proposed for the Kaposi

sarcoma-associated herpes virus (KSHV)-encoded CC chemokine vMIP-III. It is
a CCR4 agonist that selectively attracts Th2 cells [278]. Since the host response
to viral infection is mainly Th1-mediated [279], the recruitment of Th2 cells and
down-regulation of Th1 responses would be beneficial for HCMV [118, 119].
In order to examine the amplifier model, we measured CCL22 levels
following vCXCL-1 exposure (Fig. 14). CCL22 is a potent chemoattractant for
monocytes, dendritic cells, NK cells, and the Th2 cells [267]. HCMV induction of
CCL22 could lead to an influx of cells that could then be used as a vehicle for
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dissemination and/or alter the Th status allowing for delayed viral clearance.
Analysis of CCL22 transcript levels found that vCXCL-1s can induce CCL22
production (Fig. 14). vCXCL-1Tol, vCXCL-1E760, and vCXCL-1C952 showed high
induction of CCL22 similar to CXCL1.

Interestingly, CCL22 levels paralleled

vCXCL-1 affinity for CXCR2 and ability to bind to CXCR1.

In the case of

secondary chemokine secretion, affinity does correlate with CCL22 production.
Unlike CCL22 induction, calcium flux, integrin expression and chemotaxis
patterns did not correspond with chemokine receptor affinity.

For example,

vCXCL-1Tol, vCXCL-1C952, and vCXCL-1E760, the intermediate responders in
chemotaxis, showed high binding affinities to CXCR2 (and the ability to bind to
CXCR1) and high levels of CCL22 induction. Conversely, vCXCL-1C954, a high
responder in chemotaxis, showed low binding affinity to CXCR2 and low
induction of CCL22. vCXCL-1TX24 also showed similar results to vCXCL-1C954.
Only vCXCL-1TX15, a non-ELR CXC chemokine, showed a correlation between
these assays: low binding affinity, low response in chemotaxis, and no change in
CCL22 induction. But vCXCL-1TX15 also showed similar calcium flux and integrin
upregulation patterns as well other vCXCL-1s. It is possible that vCXCL-1TX15 has
different functions in vivo through calcium flux and integrin induction without
complete neutrophil activation.
Discrepancy in the results between binding affinity, chemotaxis, and
CCL22 induction profiles could be explained through functional selectivity of a
receptor [72, 280]. G protein-coupled receptors (GPCR) are allosteric proteins
that are capable of adopting different conformations, which can lead to changes
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in downstream effector proteins such as the G-proteins or β-arrestins. Different
active conformations are stabilized with the different chemokines leading to
stimulation of down stream signaling. For example, a high affinity agonist of the
5-HT2C serotonin receptor, a GPCR in same class as the chemokine receptors,
bufotenin [281] preferentially activates the phospholipase A2 (PLA2)-dependent
arachidonic acid (AA) release.

While another high affinity agonist, quipazine

[282], favors the phospholipase C (PLC)-mediated inositol phosphate (IP)
accumulation pathway [283].

This model of GPCR activation supports that

different vCXCL-1s activation of CXCR2 (and CXCR1) promotes conformational
changes leading to specific signaling outcomes.
In conclusion, our data suggest that the polymorphisms in the HCMV viral
chemokine, vCXCL-1, bind to CXC chemokine receptors with different affinities
and elicit various degrees of cellular responses through triggering of diverse
downstream signals. This could potentially contribute to HCMV pathogenesis by
accelerating viral dissemination and/or manipulating the host immune responses.
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This work is

Chapter 5
SUMMARY AND CONCLUSIONS

Human cytomegalovirus contains a CXC chemokine homolog gene,
UL146, encoding vCXCL-1.

Previously, vCXCL-1 from the Toledo strain,

vCXCL-1Tol, was shown to be a functional chemokine for chemotaxis and
intracellular calcium mobilization in human neutrophils with equivalent potency to
host chemokines [143]. vCXCL-1Tol can bind both CXCR1 and CXCR2 that are
preferentially expressed on neutrophils [284] although it was initially reported to
bind only CXCR2 [143].

Again, the functional ability of vCXCL-1Tol to both

receptors is similar to that of the host chemokine, CXCL8 (IL-8), even though its
affinity for each receptor is not as good as CXCL8 (IL-8). Because HCMV can
infect and replicate abortively in PBN, vCXCL-1’s recruitment of PBN could be
beneficial for HCMV [285]. Gerna et al showed viral transmission from HCMVinfected endothelial cells to PBN in vitro after as little as 1 hour of coculture [285].
HCMV transmission was prevented by lack of contact between the two cell
populations or by the use of monoclonal antibodies against adhesion molecules
CD18 and/or ICAM-1. Therefore, they suggested transient microfusion events as
a major viral transfer mechanism. The PBN life cycle is believed a one-way trip
that ends with apoptosis and/or necrosis in a tissue [286, 287], we believe PBN
can pick up HCMV from endothelial cells through transitory microfusion events
and

disseminate

HCMV

through

the

transendothelial migration [252] (Fig. 15).
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bloodstream

without

performing

Figure 15. PBN associated viral dissemination models.
(A) PBNs are attracted by host chemokines. (B) PBN shuttle model: vCXCL-1s
attract more PBNs. PBNs are used for viral dissemination. (C) PBN amplifier
model: vCXCL-1s induce chemokine production from PBN for attraction of other
leukocytes such as monocytes, dendritic cells, or Th2 cells.
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There are two models for the role of vCXCL-1s in HCMV dissemination
(Fig. 15). First, the neutrophil shuttle model proposes that the neutrophil is the
main vehicle for HCMV dissemination [271].

The receptors of vCXCL-1s,

CXCR1 and/or CXCR2, are expressed to high levels on neutrophils. Therefore,
neutrophils can be attracted by vCXCL-1s and can be used a vehicle for HCMV
dissemination. In addition to neutrophils, however, CXCR1 and/or CXCR2 have
been detected on monocyte/macrophages, eosinophils, basophils, CD8 T cells,
mast

cells,

and

dendritic

cells

[288-295].

HCMV

infection

in

monocytes/macrophages, dendritic cells, CD4 T cells and CD8 T cells were
reported [252, 275-277, 296]. Therefore, although functional roles of CXCR1 and
CXCR2 in theses cell types in vivo have not been fully understood, HCMV could
utilize these cells for possible means for dissemination.
The second model for the relationship between the viral chemokine and
neutrophil is the neutrophil amplifier model. This model focuses the downstream
effects of neutrophil activation.

In this model, vCXCL-1 leads to neutrophil

degranulation or expression of cytokines and/or chemokines that promote a
second inflammatory response that would contribute to HCMV dissemination.
Either of these scenarios is possible and our data suggests that perhaps both are
feasible.
Interestingly, the vCXCL-1s from different HCMV strains are hypervariable
[26, 27, 155-160] and single nucleotide polymorphisms (SNPs) has been found in
both CXCR1 and CXCR2 [297, 298].

While the strong association was not

observed between identified SNPs in CXCR1 and/or CXCR2 from patients with
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various diseases, such as rheumatoid arthritis, Behçet's disease, or Kawasaki
disease [297, 299, 300], recently SNPs in CXCR2 can increase their
susceptibility to periodontitis [301]. Therefore, their variability with in the CXCR
receptor could lead to combinatorial triggering of different signal transduction
pathways that could be related to clinical manifestations presented in the
patients. Although the hypothesis of this research is that polymorphisms in the
HCMV chemokine, vCXCL-1, elicit different functions or different levels of cellular
activation that result in determinant factors of HCMV pathogenesis, the given
SNP in the receptors could also play role in pathogenesis.
To address this, we initially compared the amino acid sequences of
vCXCL-1s from 51 clinical isolates from 50 congenitally infected children [160].
18 isolates displayed clinical manifestations such as low birth weight,
microcephaly, hepatosplenomegaly, jaundice, petechiae, or chorioretinitis. The
mature forms without the signal sequence contained between 93 and 98 residues
with 5% identity (6 residues) (Fig. 2). This includes the four cysteine residues that
provide the essential structure for CXC chemokines [107]. All sequences were
assigned to 11 distinct vCXCL-1 clades (Fig. 3).

We found no statistical

significance between the polymorphisms of vCXCL-1 sequences and HCMV
sequelae (p=0.37), although three clades showed a high proportion of
asymptomatic patients: group 8 (88%), group 10 (100%), and group 12 (83%).
To address whether the vCXCL-1 accumulates mutations under immune
selection pressure, we analyzed serial HCMV isolates and found no changes in
vCXCL-1 sequences for up to three years (Fig. 8).
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Among the differences in alignment, the vCXCL-1TX15 replaces the
glutamic acid-leucine-arginine (ELR) with the asparagine-glycine-arginine (NGR)
motif while the other 10 clades have a conserved ELR motif (Fig. 2). Because
the ELR motif is important for receptor binding and activation [237, 238],
modification of the ELR motif could have profound effects on chemokine function.
Another important receptor binding site, the N-loop region, was also analyzed [36,
106, 107]. The N-loop region resides between the second cysteine and the 310helical turn (approximately 8-10 residues). Analysis of N-loop sequences divides
the chemokines into the same 11 clades indicating that the N-loop region is
mainly responsible for vCXCL-1 variability (Fig. 4). Since hypervariability occurs
within binding motifs, such as ELR and N-loop, vCXCL-1s may have different
affinities for the chemokine receptors and could trigger different downstream
signaling and subsequent functions.
In order to address functional variability of the vCXCL-1s, we generated
recombinant vCXCL-1s from each clade and measured binding affinities and
performed several functional assays to assess how vCXCL-1 variability affects
function. Since the majority of vCXCL-1s contain the conserved ELR motif and
vCXCL-1Tol binds to both CXCR1 and CXCR2 [28], we measured binding of
vCXCL-1s to these receptors. All vCXCL-1s were able to compete with radiolabeled CXCL8 for binding to CXCR2 with lower affinities compared to CXCL8
(Fig. 10A).

Nevertheless, three vCXCL-1s, vCXCL-1Tol, vCXCL-1C952, and

vCXCL-1E760, showed a higher affinity compared to others.

Interestingly, the

non-ELR CXC chemokine, vCXCL-1TX15, also bound to CXCR2 albeit with very
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reduced affinity. When we examined vCXCL-1 binding affinity to CXCR1, we
found a trend that vCXCL-1s with high affinity to CXCR2 receptors can also bind
CXCR1 (Fig. 10B), which is similar to CXCL8 which binds to both CXCR1 and
CXCR2.
We measured calcium mobilization to evaluate vCXCL-1s ability to
activate neutrophils and induction of adhesion molecules that may contribute to
cell-mediated viral dissemination.

All vCXCL-1s showed similar activation

potentials (Fig. 11) indicating that recombinant vCXCL-1s are capable of inducing
PBN activation and receptor affinities do not affect calcium mobilization. vCXCL1TX15 also activated PBNs at equivalent levels compared to other vCXCL-1s, but
was inhibited by a CXCR2-specific inhibitor suggesting vCXCL-1TX15 activates
PBNs exclusively through CXCR2. β2-integrins are important in the adhesion
and extravasation of circulating neutrophils across the endothelium. All vCXCL-1
differentially upregulated CD11b and CD11c at equivalent levels to host
chemokine CXCL1, although any distinct differences in activation potentials
among the vCXCL-1s were not detected (Fig. 12).
Based on the binding information of CXCR1 and CXCR2, we analyzed
chemotactic functions of vCXCL-1s on human PBNs. Because CXCL8 (IL-8)
and vCXCL-1Tol are potent chemoattractants of neutrophils [102, 143] and there
were little differences in PBN activation between vCXCL-1s (Fig. 11), it was
surprising when the vCXCL-1s showed different potencies in the induction of
neutrophil migration (Fig. 13). Interestingly, the differences in neutrophil migration
potency did not correlate with the differences in affinity for CXCR2 or CXCR1
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(Fig. 10).

For example, vCXCL-1C954 showed the highest chemotactic index

among vCXCL-1s, but had one of the lowest affinities (EC50 > 82.2 nM).
Another functional difference was observed in the induction of CCL22
(macrophage-derived chemokine (MDC)) production of neutrophil-like HL60 T2
cells upon vCXCL-1 treatment (Fig. 14). CCL22 (MDC) attracts multiple immune
cells, including monocytes, dendritic cells, and the Th2 cells [267]. Although
neutrophils are the main target for vCXCL-1s and can be used as a vehicle for
dissemination, the life span of a neutrophil is limited: only a few hours to a few
days, and they do not multiply. Monocytes and dendritic cells, on the other hand,
can survive for months and can multiply. Therefore, the induction of CCL22
(MDC) can help HCMV dissemination.

Furthermore, HCMV can productively

infect macrophages and dendritic cells while they infect neutrophils only
abortively [252, 272, 302]. An increase in Th2 responses also can help HCMV
pathogenesis by diminishing CTL responses [118, 119]. From the real-time PCR
analysis, we found that vCXCL-1s differentially induce CCL22 (MDC) production
in vitro.

Interestingly, CCL22 (MDC) induction correlated with affinity, unlike

chemotaxis analysis (Fig. 10).

For example, vCXCL-1C952, vCXCL-1E760, and

vCXCL-1Tol, showed high affinity for CXCR2 and the highest CCL22 production.
In conclusion, this study is the first to characterize 11 different HCMV viral
chemokines, vCXCL-1s. We showed they are functionally similar to each other
and to CXCL1 in intercellular calcium mobilization and adhesion molecule
induction. There was no correlation between the neutrophil functional data and
the three clades that trended towards asymptomatic outcomes. However, we
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also showed they are functionally different to each other in chemotaxis in an
affinity independent manner and secondary chemokine production (CCL22) in an
affinity dependent manner. There may be other chemokine functions that did not
show high activity in chemotaxis and CCL22 (MDC) production because all
vCXCL-1s activate PBN at comparable levels of host chemokines. Future work
such as the investigation of signal transduction pathways will clarify the
polymorphisms of vCXCL-1 at the molecular level and provide a better
understanding of vCXCL-1 and its role in HCMV pathogenesis.
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Protein production of other viral chemokines

Introduction
GPCMV encodes a unique, MIP-1 CC chemokine homolog, GPCMV-MIP
[148]. This gene encodes an 11 kDa protein, which then yields an 8.6 kDa
mature polypeptide.

Functional assays showed that GPCMV-MIP mobilizes

intracellular calcium mobilization and chemotaxis via CCR1 receptor exclusively
[149].

The intracochlear inoculation of a recombinant GPCMV lacking the

GPCMV-MIP homolog resulted in less hearing loss compared to wild type
GPCMV infection [186] indicating GPCMV-MIP has roles in CMV pathogenesis.
The UL147 ORF in HCMV encodes CXC chemokine homolog, vCXCL-2
[25]. Functional assays of vCXCL-2 are lacking because UL147 is less variable
than UL146 (i.e. not that many differences between strains) [160] and protein
production has not been successful. Recently, it was suggested that vCXCL-2 is
not secreted and is able to reduce NK activation by downregulating a NKG2D
receptor ligand, ULBP3 (IHW workshop 2010).
Previously, viral chemokine productions of GPCMV-MIP and vCXCL-2
were attempted in our lab but was unsuccesful. GPCMV-MIP ORF was cloned
into the baculovirus transfer plasmid pVL1392 and UL147 ORF was cloned into
TA vector.

This appendix is follow-up study for those viral chemokine

productions.
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Materials and Methods

Checking the sequence integrity in vectors
Previously, the UL147 ORF with an additional 6-His tagged sequence was
cloned into the baculovirus transfer plasmid pVL1392 (Invitrogen), which contains
homologous regions for recombination into the baculovirus genome. To check its
integrity, the forward and reverse polyhedrin primers were purchased (Invitrogen)
and used for the DNA sequencing. The polyhedrin primer regions are located
outside of the multi cloning site (MCS). The GPCMV-MIP ORF with 6-Hig tag
was cloned into the TA vector. To check its integrity, SP6 and T7 primer were
used for DNA sequencing.

Site-Directed Mutagenesis
To fix a single nucleotide substitution of UL147 in pVL1392 vector, the
site-directed

mutagenesis

technique

was

conducted

using

primers

(UL147_Fix_Foward: 5’-GAAGTGCTGGCTATTTTAAAGGACAAGGGAACCAAG
-3’; UL147_Fix_Reverse : 5’-CGTTAGGATTGAGACACTTGGTTCCCTTGTC-3’).
The PCR condition was 95 °C for 15 min, 35 cycles of 95 °C for 1 min, 55 °C for
1 min, and 72 °C for 18 min. The reaction was extended at 72 °C for 15 min.
DpnI treatment was used to elimnate the original (unmutated) DNA strand. PCR
was cleanuped using a QIAquick PCR purification kit (QIAGEN) and transformed
into MAX Efficiency DH5α competent cells (Invitrogen). After 16 hr incubation
the colonies were picked and miniprepped for sequencing.
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Transfer of GPCMV-MIP from TA to pVL1392
To clone out GPCMV-MIP ORF from TA vector and to delete a redundant
5’ sequence preceding the start codon, PCR amplification was performed using
primers (GP526_Fix_Forward: 5’-GCGCTGCAGATGAGAAAGATGAGAGCTTA
TCTTGGCACAG-3’; GP526_Fix_Reverse: 5’-TCGGAATTCTTAGTGGTGGTGG
TGGTGGTGTCCTCCGGCCTG-3’). The forward primer has PstI restriction
enzyme site and the reverse primer has an EcoRI site to give them the correct
orientation in pVL1392. The PCR condition was 95 °C for 15 min, 35 cycles of
95 °C for 1 min, 55 °C for 1 min, and 72 °C for 5 min. The reaction was extended
at 72 °C for 10 min.

The PCR-amplified GPCMV-MIP was cloned into the

pVL1392 vector (Invitrogen) using PstI and EcoRI double digestion. To check
the gene integrity, DNA sequencing was performed using the polyhedrin primers
(Invitrogen).

Production of recombinant viral chemokines
For the generation of baculoviruses, SF9 cells were transfected with the
1392/viral

chemokine

ORF

plasmid

construct

and

Sapphire

linearized

baculovirus DNA (Orbigen) according to the manufacturer’s instructions.
Recombinant baculovirus containing the viral chemokine gene was titrated in the
small scale (2 ml) of Hi5 cells for optimum protein expression. Based on the
small scale titration, the large scale (350-400 ml) of Hi5 cells were used for
protein production.

48 hrs after infection, supernatants were harvested and
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recombinant proteins were isolated from the supernatants using Ni-NTA agarose
beads (Qiagen) for 2 hrs incubation in cold room. Harvested Ni-NTA agarose
beads were washed 3 times with PBS. Proteins were eluted from the beads
using 0.5 M imidazole for 2 times of 10 min incubation at cold room on the
rocker.

Eluted proteins were concentrated by Amicon Ultra Centrifugal Filter

Units (Millipore) with 3 kDa molecular weight cut off.

Result and Discussion

GPCMV-MIP protein production
GPCMV-MIP ORF was cloned into TA vector. DNA sequencing revealed
that it has a redundant nucleotide preceding start codon (Fig. 16A). Furthermore,
restriction enzyme sites flanking the ORF were EcoRI, which does not provide an
orientation upon cloning into pVL1392. Therefore, when we clone out this ORF
from the TA vector and put it into pVL1392, we designed primers containing
different restriction enzyme sites, PstI and EcoRI. Expected PCR product, a 348
bp band, was observed (Fig. 17A). After the PCR product was extracted from
the gel, both pVL1392 vector and PCR product were double digested by PstI and
EcoRI (Fig. 17B). To get rid of any non-specific DNA fragment, digested bands
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Figure 16. The sequences of GPCMV-MIP and UL147 ORF from previous
work.
The orange color region is the actual ORF sequences.

The start and stop

codons are boxed. (A) GPCMV-MIP ORF cloned into the TA vector showed a
additional 5’-sequences preceding start codon. In addition, all restriction enzyme
sites were EcoRI.

(B) UL147 ORF cloned into pVL1392 showed a

nonsynonymous substitution.
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Figure 17. PCR and Cloning of GPCMV-MIP into pVL1392
(A) Primers with PstI or EcoRI enzyme sites produced 348 bp PCR product. (B)
348 bp band was extracted and double digested with PstI or EcoRI. pVL1392
vector also double digested with the same restriction enzymes. (C) To remove
non-specific DNA fragments, double digested DNAs were extracted from the gel.
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were extracted (Fig. 17C). Then, the PCR product was ligated into pVL1392
vector. After bacterial amplification of 1392/GPCMV-MIP ORF plasmid construct,
DNA sequencing confirmed its integrity again (data not shown).
Transfection/infection into SF9 cells was performed to produce GPCMVMIP ORF-containing baculovirus. When cytopathic effect (CPE) was observed in
over 90% of SF9 cells, the supernatant containing baculovirus was harvested.
Small scale of Hi5 cells (2 ml) was used to titrate the baculoviral stock for
optimum protein expression. 900ul of Hi5 supernatants, 100ul of 10xHBS and
50ul of Ni-NTA agarose beads (Qiagen) were incubated for 2 hrs and the amount
of purified protein confirmed on a silver stained SDS PAGE gel. The expected
9.4 kDa protein was detected in supernatants from Hi5 cells infected with 10 ul
input of baculoviral stock (Fig. 18A). The following large scale production was
also successful.

Interestingly, another 16kDa band appeared in large-scale

production (Fig. 18C). There is one N-glycosylation site (N79) in GPCMV-MIP,
we suspect the 16kDa protein is a glycosylated form of GPCMV-MIP. PNGaseF
treatment confirmed it is a glycosylated form as it is deacreased to the 9.4kDa
upon treatment (Fig. 19).

vCXCL-2 protein production
UL147 ORF was already cloned into pVL1392 vector. DNA sequencing with
polyhedrin primers revealed that it contained a nonsynonymous substitution (A →
G), which changes lysine to glutamic acid (Fig. 16B). Therefore, we performed
site-directed

mutagenesis

PCR

to
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fix

the

substitution.

This

Figure 18. GPCMV-MIP and vCXCL-2 production.
(A) Small scale baculoviral stock titration for GPCMV-MIP production. The
expected 9.4 kDa band begins to appear at 10 ul input supernatant.

(B)

Baculoviral stock titration for vCXCL-2 in small scale. Expected 8.8 kDa band
started to appear in 100 ul input supernatant. (C) Large scale protein production.
Two distinct bands were observed in GPCMV-MIP while no protein product in
vCXCL-2 production.
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Figure 19. PNGaseF confirms GPCMV-MIP glycosylation.
PNGaseF treatment confirms that a 16 kDa protein is a glycosylated GPCMVMIP as it is reduced in size upon treatment.
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mutagenesis was successfully performed and confirmed by DNA sequencing
(data not shown).
Transfection/infection of SF9 cells was performed to produce UL147 ORFcontaining baculovirus. When cytopathic effect (CPE) was observed in over 90%
of SF9 cells, the supernatant containing baculovirus was harvested. Small scale
infection of Hi5 cells (2 ml) was used to titrate the baculoviral stock for optimum
protein expression. The expected 8.8 kDa protein was observed in a 100 ul
infection of baculoviral stock (Fig. 18B). Following large-scale production,
however, no protein was isolated (Fig. 18C).
Penfold et al showed GPCMV-MIP is a functional CC chemokine as it
induces chemotaxis in hCCR1 expressing L1.2 cells [149]. However, multiple
minor bands were shown in their SDS-PAGE gel. They speculated those minor
bands might be multimers of the 18 kDa species because they did not see any
mobility of the proteins with endoglycosylase PNGase F. In contrast, we only
had two bands in SDS-PAGE and 16 kDa band was disappeared with PNGase F
treatment. Therefore, we believe our GPCMV-MIP has much higher purity, which
could generate different results in chemokine function in the same hCCR1
expressing L1.2 cells or guinea pig cells expressing CCR1 such as neutrophils or
monocytes.
Interestingly, UL147 ORF-containing baculovirus expresses protein in a
small scale but not in a large scale. To confirm whether the protein in a small
scale is actually vCXCL-2, western blotting with an antibody against the 6 His tag
could be carried out. If it is right protein, then protein production on a large scale
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could be followed. The possible reasons for why we were not able to purify
protein on a large scale may be the incorrect volume of viral inoculation or simply
non-optimal growth conditions for the cells. If we are able to purify soluble
vCXCL-2, we can test it all the functional assays for chemokines, such as binding
assay, calcium mobilization, and chemotaxis.

Because vCXCL-2 protein

production in soluble form has been unsuccessful, it will certainly help to build
our knowledge about HCMV pathogenesis as well as being a potential novel
chemokine.
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